Olfactory ensheathing cells	1
duration	36
autonomic dysreflexia in rats with high spinal cord injury Tomáš Kalinčík a ,	48
autonomic dysreflexia	48
rats with high spinal cord injury Tomáš Kalinčík a ,	73
rats	73
high spinal cord injury Tomáš Kalinčík a ,	83
high spinal cord injury Tomáš Kalinčík	83
a	124
Eun A. Choi a	129
Eun A. Choi	129
a	141
François Féron b	144
John Bianco b	162
John Bianco	162
b	174
Ratneswary Sutharsan b	177
Ian Hayward b	201
Ian Hayward	201
b	213
Alan Mackay-Sim b	216
Pascal Carrive a	235
Pascal Carrive	235
a	250
Phil M.E. Waite a a School of Medical Sciences , University of New South Wales	253
Phil M.E. Waite	253
a a School of Medical Sciences , University of New South Wales	269
a School	271
Medical Sciences	283
University of New South Wales	301
University	301
New South Wales	315
Sydney	332
NSW 2052	340
Australia b Eskitis Institute for Cell and Molecular Therapies	350
Australia b Eskitis Institute	350
Cell and Molecular Therapies	384
Griffith University	414
Nathan	435
QLD 4111	443
Australia	453
a b	464
t r	470
a c t Autonomic dysreflexia	474
a c t	474
Autonomic dysreflexia	480
a common complication in high spinal cord injury	505
a common complication	505
high spinal cord injury	530
serious consequences and death	572
we	609
the effect of acute transplantation of olfactory ensheathing cells	626
the effect	626
acute transplantation of olfactory ensheathing cells	640
acute transplantation	640
olfactory ensheathing cells	665
cardiovascular functions in rats	696
cardiovascular functions	696
rats	724
T4 transection	736
radio-telemetric recording in conscious animals	752
radio-telemetric recording	752
conscious animals	782
blood pressure and heart rate	818
rest	851
autonomic dysreflexia for up to 8 weeks	867
autonomic dysreflexia	867
up to 8 weeks	893
Olfactory ensheathing cells from syngeneic rats	920
Olfactory ensheathing cells	920
syngeneic rats	953
the injury site	989
control animals	1006
culture medium	1031
the study end point	1055
we	1076
morphometric features of sympathetic preganglionic neurons	1088
morphometric features	1088
sympathetic preganglionic neurons	1113
the injury	1163
T4 transection	1175
a fall	1202
mean arterial pressure and an increase	1220
mean arterial pressure	1220
an increase	1247
heart rate	1270
Colorectal distension , used to trigger autonomic dysreflexia ,	1282
Colorectal distension	1282
autonomic dysreflexia	1321
episodic hypertension and bradycardia	1351
the cell transplantation	1399
no effect on resting cardiovascular parameters	1428
no effect	1428
cardiovascular parameters	1449
it	1476
a significantly faster recovery	1486
hypertension	1523
the recovery time	1542
approximately 25 %	1573
The transection	1592
an increase in soma size of sympathetic preganglionic neurons	1620
an increase	1620
soma size of sympathetic preganglionic neurons	1635
soma size	1635
sympathetic preganglionic neurons	1648
the injury	1698
OEC transplantation	1710
this change	1741
the injury	1759
dendritic length of preganglionic neurons	1784
dendritic length	1784
preganglionic neurons	1804
the injury	1832
controls	1856
It	1866
changes in sympathetic preganglionic neurons following spinal cord transection	1892
changes	1892
sympathetic preganglionic neurons following spinal cord transection	1903
sympathetic preganglionic neurons	1903
spinal cord transection	1947
the development of autonomic dysreflexia	1989
the development	1989
autonomic dysreflexia	2008
Our results	2031
olfactory ensheathing cells	2056
the morphology of these neurons	2094
the morphology	2094
these neurons	2112
their activity	2144
the neuronal networks responsible for the dysreflexic reaction	2162
the neuronal networks	2162
the dysreflexic reaction	2200
Introduction Spinal cord injury	2230
Introduction	2230
Spinal cord injury	2243
SCI	2263
the cervical and high thoracic level	2271
associatedwith cardiovascular dysfunction	2311
Mathias and Frankel , 1999 ; Osborn et al. , 1990 ; Teasell et al. , 2000	2354
Mathias and Frankel	2354
Mathias	2354
Frankel	2366
1999 ; Osborn et al.	2375
1999	2375
Osborn et al.	2381
Osborn	2381
et al.	2388
1990 ; Teasell et al. , 2000	2396
1990	2396
Teasell et al. , 2000	2402
Teasell	2402
et al. , 2000	2410
et al.	2410
2000	2418
This	2425
a decrease	2454
the basal level	2468
the mean arterial pressure -LRB- MAP -RRB-	2487
the mean arterial pressure	2487
MAP	2515
orthostatic hypotension , loss of diurnal variation ,	2521
orthostatic hypotension	2521
loss of diurnal variation	2546
loss	2546
diurnal variation	2554
autonomic dysreflexia -LRB- Frankel et al. , 1972 ; Krum et al. , 1991 -RRB-	2577
autonomic dysreflexia	2577
Frankel	2600
et al. , 1972 ; Krum et al. , 1991	2608
et al.	2608
1972 ; Krum et al.	2616
1972	2616
Krum et al.	2622
Krum	2622
et al.	2627
1991	2635
Autonomic dysreflexia	2642
48	2674
70 %	2677
patients	2684
high level lesions -LRB- i.e. at or above T6 -RRB- -LRB- Karlsson , 1999 -RRB-	2698
high level lesions -LRB- i.e. at or above T6 -RRB-	2698
high level lesions	2698
i.e. at or above T6	2718
i.e.	2718
T6	2735
Karlsson	2740
1999	2750
It	2757
a sudden exaggerated increase in blood pressure and a drop	2780
a sudden exaggerated increase	2780
blood pressure and a drop	2813
blood pressure	2813
a drop	2832
heart rate -LRB- HR -RRB-	2842
heart rate	2842
HR	2854
inappropriate responses	2875
the sympathetic nervous system	2902
stimuli originating below the injury level , such as bowel or bladder distension	2936
stimuli	2936
the injury level , such as bowel or bladder distension	2962
the injury level	2962
bowel or bladder distension	2988
Karlsson , 1999 ; Teasell et al. , 2000	3017
Karlsson	3017
1999 ; Teasell et al.	3027
1999	3027
Teasell et al.	3033
Teasell	3033
et al.	3041
2000	3049
The hypertension in autonomic dysreflexia	3056
The hypertension	3056
autonomic dysreflexia	3076
serious complications and death -LRB- Mathias and Frankel , 1999 -RRB-	3125
serious complications	3125
death -LRB- Mathias and Frankel , 1999 -RRB-	3151
death	3151
Mathias and Frankel , 1999	3158
Mathias and Frankel	3158
1999	3179
Several pathophysiological mechanisms	3186
autonomic dysreflexia	3249
loss of tonic bulbospinal projections to spinal sympathetic neurons	3293
loss	3293
tonic bulbospinal projections to spinal sympathetic neurons	3301
tonic bulbospinal projections	3301
spinal sympathetic neurons	3334
changes in small-diameter peptidergic afferent fibres	3362
changes	3362
small-diameter peptidergic afferent fibres	3373
increase in density of lumbosacral propriospinal projections	3417
increase	3417
density of lumbosacral propriospinal projections	3429
density	3429
lumbosacral propriospinal projections	3440
alterations in input	3479
alterations	3479
input	3494
morphology of the sympathetic preganglionic neurons	3504
morphology	3504
the sympathetic preganglionic neurons	3518
the injury	3566
vascular hyper-responsiveness	3582
Arnold	3613
et al. , 1995	3620
et al.	3620
1995	3628
Hou et al. , 2008	3634
Hou	3634
et al. , 2008	3638
et al.	3638
2008	3646
Krassioukov and Weaver , 1995b	3652
Krassioukov and Weaver	3652
1995b	3676
Krenz et al. , 1999	3683
Krenz	3683
et al. , 1999	3689
et al.	3689
1999	3697
Llewellyn-Smith and Weaver , 2001	3703
Llewellyn-Smith and Weaver	3703
2001	3731
Ondarza et al. , 2003	3737
Ondarza	3737
et al. , 2003	3745
et al.	3745
2003	3753
All these	3760
high level cord injury	3804
the development of autonomic dysreflexia	3860
the development	3860
autonomic dysreflexia	3879
Olfactory ensheathing cells -LRB- OECs -RRB-	3902
Olfactory ensheathing cells	3902
OECs	3931
regeneration	3967
damaged nervous tissue	3983
their good accessibility	4027
them	4059
candidates	4074
reconstructive treatment	4089
spinal cord injury	4117
Iwatsuki et al. , 2008 ; Li et al. , 2003 , 1997 ; Ramon-Cueto , 2000	4137
Iwatsuki et al.	4137
Iwatsuki	4137
et al.	4146
2008 ; Li et al.	4154
2008	4154
Li et al.	4160
Li	4160
et al.	4163
2003	4171
1997 ; Ramon-Cueto , 2000	4177
1997	4177
Ramon-Cueto , 2000	4183
Ramon-Cueto	4183
2000	4196
Studies in rodentmodels	4203
Studies	4203
rodentmodels	4214
the potential of OECs	4245
the potential	4245
OECs	4262
re-myelination and long-distance regrowth of axons	4278
re-myelination and long-distance regrowth	4278
axons	4323
the injured spinal cord	4336
improvement	4384
locomotor performance	4399
SCI	4431
Li	4436
et al. , 2003 , 1998 ; Lu et al. , 2001 , 2002 ; Ramon-Cueto et al. , 1998	4439
et al.	4439
2003 , 1998 ; Lu et al. , 2001 , 2002 ; Ramon-Cueto et al.	4447
2003 , 1998	4447
2003	4447
1998	4453
Lu et al. , 2001 , 2002	4459
Lu	4459
et al. , 2001 , 2002	4462
et al.	4462
2001	4470
2002	4476
Ramon-Cueto et al.	4482
Ramon-Cueto	4482
et al.	4494
1998	4502
Clinical trials with OEC transplantation	4509
Clinical trials	4509
OEC transplantation	4530
Feron et al. , 2005 ; Mackay-Sim et al. , 2008	4571
Feron	4571
et al. , 2005 ; Mackay-Sim et al. , 2008	4577
et al. , 2005	4577
et al.	4577
2005	4585
Mackay-Sim et al. , 2008	4591
Mackay-Sim	4591
et al. , 2008	4602
et al.	4602
2008	4610
the effect of the OECs on cardiovascular disorders associated with SCI	4626
the effect	4626
the OECs on cardiovascular disorders associated with SCI	4640
the OECs	4640
cardiovascular disorders associated with SCI	4652
cardiovascular disorders	4652
SCI	4693
The research work reported in this manuscript	4720
The research work	4720
this manuscript	4750
radiotelemetric recording -LRB- Carrive , 2000 -RRB-	4775
radiotelemetric recording	4775
Carrive	4802
2000	4811
the effect of acute OEC transplantation	4832
the effect	4832
acute OEC transplantation	4846
the recovery	4875
cardiovascular functions following T4 spinal cord transection in conscious rats	4891
cardiovascular functions	4891
T4 spinal cord transection in conscious rats	4926
T4	4926
spinal cord transection in conscious rats	4929
spinal cord transection	4929
conscious rats	4956
We	4972
OECs	4993
cardiovascular parameters	5022
dysreflexia	5062
i.e.	5075
the peak MAP	5089
the duration of hypertension associated with autonomic dysreflexia	5114
the duration	5114
hypertension associated with autonomic dysreflexia	5130
hypertension	5130
autonomic dysreflexia	5159
Survival of the OEC transplants	5183
Survival	5183
the OEC transplants	5195
one of the possible mechanisms of the OEC effect	5233
one	5233
the possible mechanisms of the OEC effect	5240
the possible mechanisms	5240
the OEC effect	5267
the morphology of sympathetic preganglionic neurons	5306
the morphology	5306
sympathetic preganglionic neurons	5324
Materials and methods All experimental protocols and procedures	5363
Materials	5363
methods All experimental protocols and procedures	5377
methods	5377
All experimental protocols and procedures	5385
the Animal Care and EthicsCommittee of theUniversity ofNewSouthWales	5444
the Animal Care	5444
EthicsCommittee of theUniversity ofNewSouthWales	5464
EthicsCommittee	5464
theUniversity ofNewSouthWales	5483
the rules and guidelines on animal experimentation	5530
the rules and guidelines	5530
animal experimentation	5558
Australia	5584
Experiments	5595
37 naive male Australian Albino Wistar rats	5625
Biological Resources Centre , University of New South Wales , Sydney , Australia	5670
Biological Resources Centre	5670
University of New South Wales	5699
University	5699
New South Wales	5713
Sydney , Australia	5730
11	5754
14 weeks	5757
350 -- 400 g	5779
350	5779
400 g	5784
The animals	5791
groups of 3 in plastic home boxes -LRB- 65 × 40 × 22 cm -RRB-	5818
groups	5818
3 in plastic home boxes -LRB- 65 × 40 × 22 cm -RRB-	5828
3	5828
plastic home boxes -LRB- 65 × 40 × 22 cm -RRB-	5833
plastic home boxes	5833
65 × 40 × 22 cm	5853
65 × 40 ×	5853
65 ×	5853
40 ×	5856
22 cm	5859
the 3 days following radio-telemetric probe implantation	5880
the 3 days	5880
radio-telemetric probe implantation	5901
the 2 weeks following SCI , when they were housed separately	5948
the 2 weeks	5948
SCI , when they were housed separately	5970
SCI	5970
they	5980
The rats	6009
ad-lib food and water	6037
a 12-h light/dark cycle	6077
2.1	6102
Experimental design There were two separate experiments	6107
Experimental design	6107
There	6127
two separate experiments	6138
a functional study -LRB- n = 13 -RRB-	6164
a functional study	6164
n	6184
13	6186
the effect of OEC transplantation	6205
the effect	6205
OEC transplantation	6219
autonomic dysreflexia	6242
a cell survival study -LRB- n = 18 -RRB-	6268
a cell survival study	6268
n	6291
18	6293
OEC survival	6307
the cord	6323
addition	6336
a group of animals with no SCI -LRB- n = 6 -RRB-	6346
a group of animals with no SCI	6346
a group	6346
animals with no SCI	6357
animals	6357
no SCI	6370
n	6378
6	6380
their spinal cord tissue	6400
NADPH-diaphorase	6458
the morphometric features of the stained sympathetic preganglionic neurons	6479
the morphometric features	6479
the stained sympathetic preganglionic neurons	6508
the	6508
sympathetic preganglionic neurons	6520
an intact control	6580
Animals	6599
the functional experiments	6619
the radio-telemetric device	6666
monitoring of cardiovascular functions -LRB- MAP and HR -RRB-	6698
monitoring	6698
cardiovascular functions -LRB- MAP and HR -RRB-	6712
cardiovascular functions	6712
MAP and HR	6738
MAP	6738
HR	6746
One week following the probe implantation , baseline MAP and HR	6751
One week	6751
the probe implantation , baseline MAP and HR	6770
the probe implantation	6770
baseline MAP	6794
HR	6811
Two weeks	6829
the implantation	6845
the animals	6863
T4 spinal cord transection	6885
T4	6885
spinal cord transection	6888
transection	6931
the OEC-treated animals -LRB- n = 6 -RRB-	6944
the OEC-treated animals	6944
n	6969
6	6971
transplants of isogeneic OECs	6983
transplants	6983
isogeneic OECs	6998
green fluorescent protein	7024
GFP	7051
porcine collagen sponge	7077
the control animals -LRB- n = 7 -RRB-	7108
the control animals	7108
n	7129
7	7131
the sponge soaked with culture medium	7143
the sponge	7143
culture medium	7166
Cardiovascular	7182
rest	7210
autonomic dysreflexia , elicited by colorectal distension	7226
autonomic dysreflexia	7226
colorectal distension	7261
weekly between weeks	7299
weekly	7299
weeks	7314
3 -- 8 post-injury	7320
3 -- 8	7320
9 weeks	7340
the animals	7361
their spinal cord tissue	7393
β-tubulin III and GFP	7453
β-tubulin III	7453
GFP	7471
NADPHdiaphorase	7500
Evaluation of the β-tubulin III-positive fibre regrowth	7517
Evaluation	7517
the β-tubulin III-positive fibre regrowth	7531
analysis of morphometric features of the NADPH-diaphorase	7577
analysis	7577
morphometric features of the NADPH-diaphorase	7589
morphometric features	7589
the NADPH-diaphorase	7614
positive sympathetic preganglionic neurons	7635
Animals	7696
the cell survival study	7716
T4	7750
spinal cord transection and transplantation	7753
GFP-labelled OECs	7800
a procedure	7824
that used for the functional study above	7849
that	7849
the functional study	7863
7	7894
11 , 23 and 30 days post-injury , 6 , 3 , 3 and 6 animals respectively ,	7897
11	7897
23 and 30 days post-injury , 6 , 3 , 3 and 6 animals respectively	7901
23 and 30 days	7901
post-injury , 6 , 3 , 3 and 6 animals respectively	7916
post-injury , 6 , 3 , 3 and 6 animals	7916
their spinal cords	7985
GFP	8044
OEC survival	8060
2.2	8074
Implantation of radio-telemetric probes The 13 animals in the functional study	8079
Implantation	8079
radio-telemetric probes The 13 animals in the functional study	8095
radio-telemetric probes	8095
The 13 animals in the functional study	8119
The 13 animals	8119
the functional study	8137
a radio-telemetric device	8178
a standard protocol -LRB- Carrive , 2000 -RRB-	8217
a standard protocol	8217
Carrive	8238
2000	8247
rats	8263
a mixture of ketamine hydrochloride -LRB- 100 mg/kg i.p.	8292
a mixture	8292
ketamine hydrochloride -LRB- 100 mg/kg i.p.	8305
ketamine hydrochloride	8305
100 mg/kg	8329
Ketamine , Parnell Laboratories Pty. Ltd. , NSW , Australia -RRB-	8345
Ketamine	8345
Parnell Laboratories Pty. Ltd.	8355
NSW , Australia	8387
xylazine -LRB- 7 mg/kg , i.p.	8407
xylazine	8407
7 mg/kg	8417
Ilium Xylazil-20 , Troy Laboratories Pty. Ltd.	8432
Ilium Xylazil-20	8432
Troy Laboratories Pty. Ltd.	8450
NSW	8479
Australia	8484
sterile conditions	8502
the surgical site	8522
0.5 % bupivacaine hydrochloride	8576
0.1 ml ; Bupivacaine	8608
0.1 ml	8608
Bupivacaine	8616
Pharmacia Pty. Ltd. , WA , Australia	8629
Pharmacia Pty. Ltd.	8629
WA , Australia	8650
a 3 -- 6 cm midline abdominal skin incision	8669
3	8671
6 cm midline abdominal skin incision	8673
6 cm midline	8673
abdominal skin incision	8686
The linea alba and peritoneum	8720
the abdominal aorta	8764
the inferior vena cava	8826
Silk suture	8850
the aorta	8880
traction	8894
blood flow	8923
duration of the occlusion	8935
duration	8935
the occlusion	8947
2 -- 5 min	8962
2	8962
5 min	8964
The bifurcation of the aorta	8972
The bifurcation	8972
the aorta	8991
the catheter	9028
a radio-telemetric probe	9044
PhysioTel PA-C40 , DSI , St. Paul , MN , USA	9070
PhysioTel PA-C40	9070
DSI	9088
St. Paul	9093
MN	9103
USA	9107
1 cm	9121
the abdominal aorta	9131
The catheter	9152
a cellulose patch	9180
Cellulose Patch Kit -- Small Animals	9199
Cellulose Patch Kit	9199
Small Animals	9221
DSI , St. Paul , MN , USA	9236
DSI	9236
St. Paul	9241
MN	9251
USA	9255
tissue adhesive	9264
3 M Vetbond , 3 M Animal Care Products , USA	9281
3 M Vetbond	9281
3 M Animal Care Products	9294
3 M	9294
Animal Care Products	9298
USA	9320
The aortal occlusion	9326
procaine penicillin	9369
0.25 ml ; Benacillin	9390
0.25 ml	9390
Benacillin	9399
Troy Laboratories Pty. Ltd. , NSW , Australia	9411
Troy Laboratories Pty. Ltd.	9411
NSW , Australia	9440
The body of the radio-telemetric probe	9483
The body	9483
the radio-telemetric probe	9495
the peritoneal cavity , sutured to the anterior abdominal wall at the midline	9536
the peritoneal cavity	9536
the anterior abdominal wall at the midline	9570
the anterior abdominal wall	9570
the midline	9601
the wound	9618
2.3	9640
Cell preparation Cultures of OECs	9645
Cell preparation Cultures	9645
OECs	9674
as previously described -LRB- Bianco et al. , 2004 -RRB-	9693
as previously described	9693
as previously	9693
Bianco	9718
et al. , 2004	9725
et al.	9725
2004	9733
Australian AlbinoWistarmale rats -LRB- 8 weeks of age -RRB-	9749
Australian AlbinoWistarmale rats	9749
8 weeks of age	9783
8 weeks	9783
age	9794
pentobarbitone	9830
0.5 ml i.p. ; Lethabarb , Virbac Pty. Ltd. , NSW , Australia	9846
0.5 ml i.p. ; Lethabarb , Virbac Pty. Ltd. ,	9846
0.5 ml i.p.	9846
0.5 ml	9846
Lethabarb , Virbac Pty. Ltd. ,	9859
Lethabarb	9859
Virbac Pty. Ltd.	9870
NSW , Australia	9888
decapitation	9918
the olfactorymucosawas	9937
Dulbecco	9984
sModified Eagle Medium	9993
DMEM ; Invitrogen , Auckland , New Zealand	10017
DMEM	10017
Invitrogen , Auckland , New Zealand	10023
Ham 's F12	10069
Ham 's	10069
37 °C in Dispase II	10096
37 °C	10096
Dispase II	10105
2.4 U/ml in Puck 's solution	10117
2.4 U/ml	10117
Puck 's solution	10129
Puck 's	10129
The lamina propria	10147
the olfactory epitheliumand	10190
0.25 % collagenase	10233
type IA at 37 °C	10251
type IA	10251
37 °C	10262
5 % CO2	10272
Collagenase activity	10280
Ca	10318
Mg-free Hanks ' balanced salt solution	10326
Mg-free Hanks '	10326
BioWhittaker	10365
Walkersville	10379
MD , USA	10393
the resulting cell suspension	10403
the cell pellet	10450
DMEM/HAMF12	10482
10 % fetal calf serum	10512
poly-L-lysine -LRB- 2 μg/cm2 -RRB-	10547
poly-L-lysine	10547
2 μg/cm2	10562
coated dishes	10572
Two days later	10587
the culture medium	10603
serum-free medium	10638
neurotrophin 3 -LRB- NT3 , 50 ng/ml -RRB-	10674
neurotrophin 3	10674
NT3 , 50 ng/ml	10690
NT3	10690
50 ng/ml	10695
survival of OECs in culture	10731
survival	10731
OECs in culture	10743
OECs	10743
culture	10751
their purity to close to 100 % -LRB- Bianco et al. , 2004 -RRB-	10772
100 % -LRB- Bianco et al. , 2004 -RRB-	10797
100 %	10797
Bianco	10803
et al. , 2004	10810
et al.	10810
2004	10818
tracking of the cells 9 weeks	10847
tracking	10847
the cells	10859
9 weeks	10869
transplantation	10883
OECs	10900
humanised Renilla	10935
GFP using a retrovirus based on the Moloney Murine Leukaemia Virus	10964
GFP	10964
a retrovirus	10974
the Moloney Murine Leukaemia Virus	10996
OECs	11032
pFB-hrGFP retroviral supernatant -LRB- Stratagene , La Jolla , CA , USA -RRB-	11058
pFB-hrGFP retroviral supernatant	11058
Stratagene	11092
La Jolla	11104
CA , USA	11114
6	11126
One week	11141
the transduced OECs	11157
the	11157
OECs	11172
a fluorescence-activated cell sorter -LRB- BD FACS Aria , BD Biosciences -RRB-	11195
a fluorescence-activated cell sorter	11195
BD FACS Aria , BD Biosciences	11233
BD FACS Aria	11233
BD Biosciences	11247
The viability and labelling of the modified OECs	11264
The viability and labelling	11264
the modified OECs	11295
the purpose of the present experiment	11331
the purpose	11331
the present experiment	11346
they	11373
GFP 9 weeks after injection	11411
GFP 9 weeks	11411
injection	11429
rat spinal cord	11444
other experiments	11463
our laboratory -LRB- Dr. Frank Cloutier , unpublished results -RRB-	11484
our laboratory	11484
Dr. Frank Cloutier , unpublished results	11500
Dr. Frank Cloutier	11500
unpublished results	11520
OECs	11542
antibodies	11590
p75NFR	11609
1:200 , monoclonal ; Neubody , Thebarton , SA , Australia	11617
1:200	11617
monoclonal ; Neubody , Thebarton , SA , Australia	11624
monoclonal	11624
Neubody , Thebarton , SA , Australia	11636
glial fibrillary acidic protein	11675
1:250 , polyclonal GFAP ; Dako North America Inc. , CA , USA	11708
1:250	11708
polyclonal GFAP ; Dako North America Inc.	11715
polyclonal GFAP	11715
Dako North America Inc.	11732
CA , USA	11757
90 % of cells in the OEC	11772
90 %	11772
cells in the OEC	11779
cells	11779
the OEC	11788
cultures	11796
p75NFR and GFAP immunoreactive	11810
p75NFR and GFAP	11810
a control for contaminationwithmyelinating Schwann cells	11845
a control	11845
contaminationwithmyelinating Schwann cells	11859
cultureswere	11903
HNK1 antibody -LRB- 1:200 , Sigma Castle Hill , NSW , Australia -RRB-	11947
HNK1 antibody	11947
1:200	11962
Sigma Castle Hill	11969
NSW , Australia	11988
this testing	12013
a small degree	12045
contamination -LRB- less than 5 % -RRB-	12063
contamination	12063
less than 5 %	12078
non-myelinating Schwann cells	12096
knownto lack	12136
theHNK1 epitope	12166
Bock	12192
et al. , 2007	12197
et al.	12197
2007	12205
detailed description of the reagents used	12216
detailed description	12216
the reagents used	12240
the reagents	12240
immuno - identification protocol see Bianco et al. -LRB- 2004 -RRB-	12262
immuno	12262
identification protocol	12270
Bianco	12298
et al. -LRB- 2004 -RRB-	12305
et al.	12305
2004	12313
transplantation	12330
OECs	12347
the culture flasks	12371
trypsin treatment -LRB- 0.25 % w/v -RRB-	12393
trypsin treatment	12393
0.25 % w/v	12412
0.25 %	12412
w/v	12418
centrifugation	12440
DMEM / HAMF12 -LRB- 500,000 cells/μl -RRB-	12476
DMEM / HAMF12	12476
DMEM	12476
HAMF12	12482
500,000 cells/μl	12490
2.4	12509
T4	12514
spinal cord transection and OECs transplantation	12517
The 13 rats	12566
the functional experiments -LRB- two weeks after the probe implantation -RRB-	12590
the functional experiments	12590
two weeks after the probe implantation	12618
two weeks	12618
the probe implantation	12634
18 rats	12662
the cell survival study	12682
radio-telemetric probes	12715
a combination of ketamine and xylazine	12764
a combination	12764
ketamine and xylazine	12781
Hair in the interscapular region	12813
Hair	12813
the interscapular region	12821
the area	12861
antiseptic solution	12884
The rat	12905
a sterile drape	12927
a homeothermic blanket -LRB- Harvard apparatus Ltd. , Kent , UK -RRB-	12948
a homeothermic blanket	12948
Harvard apparatus Ltd. , Kent , UK	12972
Harvard apparatus Ltd.	12972
Kent , UK	12996
rectal temperature	13010
37 ±	13047
1 °C	13050
The operation field	13056
0.5 % Bupivacaine and a 2	13097
0.5 % Bupivacaine	13097
a 2	13118
5 cmdorsal midline incision of the skin	13122
5 cmdorsal midline incision	13122
the skin	13153
the scapulae	13182
blunt dissection techniques	13202
the T3 vertebra	13231
the laminae and spinous process	13263
the laminae	13263
spinous process	13279
bone rongeurs	13308
The spinal cord	13323
microscissors at the level of T4	13370
microscissors	13370
the level of T4	13387
the level	13387
T4	13400
the transection	13407
a scalpel	13444
the lesion site	13462
several times	13478
This	13493
retraction of the spinal cord stumps	13510
retraction	13510
the spinal cord stumps	13524
the emergent gap approximately 1 mm wide	13552
the emergent gap	13552
approximately 1 mm	13569
Experimental animals -LRB- n = 6 -RRB- and the animals	13594
Experimental animals -LRB- n = 6 -RRB-	13594
Experimental animals	13594
n	13616
6	13618
the animals	13625
the cell survival study -LRB- n = 18 -RRB-	13649
the cell survival study	13649
n	13674
18	13676
transplants of sterile porcine gelatine sponge -LRB- approx. 2 × 1 × 1 mm ;	13689
transplants	13689
sterile porcine gelatine sponge -LRB- approx. 2 × 1 × 1 mm ;	13704
sterile porcine gelatine sponge	13704
2 × 1 × 1 mm	13745
2 × 1 ×	13745
2 ×	13745
1 ×	13747
1 mm	13749
Gelfoam , Pharmacia & Upjohn Co.	13755
Gelfoam	13755
Pharmacia & Upjohn Co.	13764
Kalamazoo , Mi , USA -RRB- ,	13787
Kalamazoo	13787
Mi	13798
USA	13802
2 μl of medium	13818
2 μl	13818
medium	13826
OECs modified to express GFP -LRB- 500,000 cells/μl -RRB-	13844
OECs	13844
GFP -LRB- 500,000 cells/μl -RRB-	13869
GFP	13869
500,000 cells/μl	13874
These transplants	13893
the transection site	13930
the gap between the cord stumps	13972
the gap	13972
the cord stumps	13988
A similar injury	14005
control animals	14039
n	14056
7	14058
an implant of Gelfoam	14076
implant of Gelfoam	14079
Gelfoam	14090
2 μl of DMEM	14108
2 μl	14108
DMEM	14116
all animals	14125
another Gelfoam block	14138
the dorsal surface of the spinal cord	14174
the dorsal surface	14174
the spinal cord	14196
the nervous tissue	14225
connective tissue	14261
Muscles and skin	14280
layers	14313
the wound	14329
2.5	14340
Post-operative care	14345
hind limb paralysis	14373
the animals	14394
signs of urinary and gastrointestinal tract dysfunction	14429
signs	14429
urinary and gastrointestinal tract dysfunction	14438
impaired control of body temperature	14489
impaired control	14489
body temperature	14509
the room temperature	14537
27 °C for 2 weeks	14570
27 °C	14570
2 weeks	14580
the spinal cord surgery	14606
the ratswere placed upon heating mats for several days	14634
the ratswere	14634
heating mats for several days	14659
heating mats	14659
several days	14676
their ability to thermoregulate improved	14696
Normotonic sodium chloride -LRB- 0.9 % , 5 -- 10 ml -RRB-	14738
Normotonic sodium chloride	14738
0.9 % , 5 -- 10 ml	14766
0.9 %	14766
5 -- 10 ml	14772
5	14772
10 ml	14775
2	14814
3 times	14816
the rats	14836
Animals	14874
prophylactic cephalotin	14891
60 mg/kg , s.c. ; Cephalotin Sodium , VIC , Australia	14916
60 mg/kg	14916
s.c. ; Cephalotin Sodium	14926
s.c.	14926
Cephalotin Sodium	14932
VIC , Australia	14951
5 days	14983
a preventivemeasure	14993
urinary tract infections	15021
the analgesic rimadyl	15051
5 mg/kg s.c.	15074
Carprofen , Australia Pty. Ltd. , Australia	15088
Carprofen	15088
Australia Pty. Ltd.	15099
Australia	15120
3 days	15135
The urinary bladder	15143
2	15186
3 times	15188
a period of up to 3 weeks	15206
a period	15206
up to 3 weeks	15218
autonomous bladder voidance reflexes	15238
The rats	15301
prophylactic paraffin oil	15321
bowel function	15357
Oil	15373
5 days	15394
SCI -LRB- 0.5 ml p.o. gavage -RRB-	15410
SCI	15410
0.5 ml p.o. gavage	15415
0.5 ml	15415
p.o. gavage	15422
5 days following the surgery -LRB- 1.0 ml enema -RRB-	15446
5 days	15446
the surgery -LRB- 1.0 ml enema -RRB-	15463
the surgery	15463
1.0 ml enema	15476
Inspection for skin irritation , ulcers , and haematuriawas	15491
Inspection	15491
skin irritation , ulcers , and haematuriawas	15506
skin irritation	15506
ulcers	15523
haematuriawas	15535
soiled animals	15568
andminor wounds treated	15595
andminor wounds	15595
2.6	15620
Cardiovascular recording at rest Baseline cardiovascular parameters	15625
Cardiovascular recording	15625
rest Baseline cardiovascular parameters	15653
MAP and HR	15694
MAP	15694
HR	15702
the day	15727
rest	15757
their home boxes	15765
one week prior to SCI	15786
one week	15786
SCI	15804
weeks 3 , 4 , 5 , 6 , 7 and 8 post-injury	15815
weeks	15815
3	15821
4	15824
5	15827
6	15830
7	15833
8	15839
MAP and HR at rest	15854
MAP and HR	15854
rest	15868
a period of 20 min -LRB- an average of values acquired over 3 s every 10 s -RRB-	15891
a period	15891
20 min -LRB- an average of values acquired over 3 s every 10 s -RRB-	15903
20 min	15903
an average of values acquired over 3 s every 10 s	15911
an average	15911
values	15925
3 s every 10 s	15946
3 s	15946
every 10 s	15950
2.7	15976
Colorectal distension Autonomic dysreflexia	15981
Colorectal distension	15981
Autonomic dysreflexia	16003
the method described by Krassioukov and Weaver -LRB- 1995a -RRB-	16043
the method described by Krassioukov and Weaver	16043
the method	16043
Krassioukov and Weaver	16067
1995a	16091
Colorectal distensionwas	16099
weeks 3 , 4 , 5 , 6 , 7 and 8 post-injury	16139
weeks	16139
3	16145
4	16148
5	16151
6	16154
7	16157
8	16163
autonomic dysreflexia	16182
Maiorov	16225
et al. , 1997	16233
et al.	16233
1997	16241
Marsh and Weaver , 2004	16247
Marsh and Weaver	16247
2004	16265
Marsh et al. , 2002	16271
Marsh	16271
et al. , 2002	16277
et al.	16277
2002	16285
Mayorov et al. , 2001	16291
Mayorov	16291
et al. , 2001	16299
et al.	16299
2001	16307
A 10 Fr paediatric Foley catheter -LRB- Bardex , Bard Inc. , GA , USA -RRB-	16314
A 10 Fr paediatric Foley catheter	16314
10 Fr	16316
Bardex	16349
Bard Inc.	16357
GA , USA	16368
a balloon -LRB- Fig. 1 ; diameter : 12 mm , length : 12 mm -RRB-	16382
a balloon	16382
Fig. 1	16393
Fig.	16393
1	16398
diameter : 12 mm , length : 12 mm	16401
diameter	16401
12 mm , length	16411
12 mm	16411
length	16418
12 mm	16426
the rectum and sigmoid	16466
descending colon of rats semi-restrained in a Perspex tube	16490
descending colon	16490
rats semi-restrained in a Perspex tube	16510
rats	16510
a Perspex tube	16534
1h of adjustment to the semi-restraint	16556
1h	16556
adjustment to the semi-restraint	16562
adjustment	16562
the semi-restraint	16576
the balloon	16596
1 ml of water	16636
1 ml	16636
water	16644
a period of 30s	16655
a period	16655
30s	16667
Colorectal distension	16672
60s , followed by gradual deflation of the balloon -LRB- 30 s -RRB-	16713
60s	16713
gradual deflation of the balloon -LRB- 30 s -RRB-	16730
gradual deflation	16730
the balloon -LRB- 30 s -RRB-	16751
the balloon	16751
30 s	16764
a data acquisition package	16777
Dataquest ART , Data Sciences International , MN , USA	16805
Dataquest ART	16805
Data Sciences International	16820
MN	16849
USA	16853
MAP and HR values	16859
80s preceding	16895
80s	16895
10 min	16917
the beginning	16934
colorectal distension -LRB- 3 s segments were recorded every 10 s -RRB-	16951
3 s segments were recorded every 10 s	16974
3 s	16974
segments	16978
every 10 s	17001
the colorectal distension and the cardiovascular measurements	17023
the colorectal distension	17023
the cardiovascular measurements	17053
3 times per animal and session	17099
3 times	17099
animal and session	17111
these responses	17134
The following valueswere	17170
fromthe recordedMAP and HR	17205
-LRB- i -RRB- relative MAP	17233
i	17234
HR	17254
deviations	17274
baselines	17290
averages	17313
8 measurements	17325
animal	17344
a value recorded over 3 s every 10 s prior to colorectal distension	17383
a value	17383
3 s every 10 s prior to colorectal distension	17405
3 s	17405
every 10 s	17409
colorectal distension	17429
each animal	17472
ii	17498
maxMAP and minHR	17502
the maximal relative changes inMAP and HR	17542
a rat	17596
autonomic dysreflexia	17609
iii	17633
peakMAP and peak HR	17638
a maximal relative change in	17673
a maximal relative change	17673
group responses of MAP and HR	17711
group responses	17711
MAP and HR	17730
-LRB- iv -RRB- T50MAP	17746
the time taken for theMAP response to decrease to 50 % of its peak	17776
the time	17776
theMAP response	17795
50 % of its peak	17826
50 %	17826
its peak	17833
2.8	17843
Tissue fixation and sectioning	17848
the study end point	17882
i.e. at 9 weeks for the rats in the functional experiment and at 7	17903
i.e.	17903
9 weeks for the rats in the functional experiment	17911
9 weeks	17911
the rats in the functional experiment	17923
the rats	17923
the functional experiment	17935
7	17968
11 , 23	17971
11	17971
23	17975
30 days for the rats in the cell survival study	17982
30 days	17982
the rats in the cell survival study	17994
the rats	17994
the cell survival study	18006
all animals	18032
pentobarbitone	18068
normotonic sodium chloride -LRB- 30 s -RRB-	18116
normotonic sodium chloride	18116
30 s	18144
4 % paraformaldehyde	18154
20 min ; Merck Schuchardt OHG	18175
20 min	18175
Merck Schuchardt OHG	18183
Hohenbrunn , Germany	18205
Hohenbrunn	18205
Germany	18217
Spinal cord segments T2	18227
Spinal cord segments	18227
T2	18248
T6	18251
4 % paraformaldehyde -LRB- 2 h -RRB-	18283
4 % paraformaldehyde	18283
2 h	18304
30 % sucrose -LRB- 24 h -RRB-	18327
30 % sucrose	18327
24 h	18340
a cryostat	18358
35 μm thick horizontal sections in 12 series of 4	18374
35 μm thick horizontal sections	18374
12 series of 4	18409
12 series	18409
4	18422
The sections	18425
gelatinised slides	18456
− 22 °C	18500
each animal	18511
3 series	18524
NADPHdiaphorase	18550
2 for β-tubulin III , 1 for GFP and 1	18567
2	18567
β-tubulin III , 1 for GFP and 1	18573
β-tubulin III	18573
1 for GFP	18588
1	18588
GFP	18594
1	18602
the examination of unlabelled GFP	18627
the examination	18627
unlabelled GFP	18646
The remaining 5 series were stored for use	18662
The remaining	18662
5 series	18676
use	18701
2.9	18724
Immunohistochemistry β-tubulin III , a neuronal microtubule protein ,	18729
Immunohistochemistry β-tubulin III	18729
Immunohistochemistry β-tubulin	18729
III	18760
a neuronal microtubule protein	18765
a monoclonal mouse anti-rat β-tubulin	18815
III primary antibody	18853
1:100,000	18875
T8660 , Sigma Chemical Co , MO , USA	18886
T8660	18886
Sigma Chemical Co	18893
MO	18912
USA	18916
synthetic peptide	18949
the C-terminal sequence of the human β-tubulin isotype	18984
the C-terminal sequence	18984
the human β-tubulin isotype	19011
III	19039
No cross-reactivity with other tubulin isotypes	19044
No cross-reactivity	19044
other tubulin isotypes	19069
Banerjee et al. , 1988	19106
Banerjee	19106
et al.	19115
1988	19123
GFP	19130
a polyclonal rabbit antibody	19152
1:300 , 240142 , Stratagene , La Jolla CA , USA	19182
1:300	19182
240142	19189
Stratagene	19197
La Jolla CA	19209
USA	19222
full-length humanised R. reniformis GFP purified from E. coli	19255
full-length humanised R. reniformis GFP	19255
E. coli	19309
No cross-reactivity with rodent proteins	19318
No cross-reactivity	19318
rodent proteins	19343
Han et al. , 2006	19373
Han	19373
et al.	19377
2006	19385
the tissue sections	19401
xylene and 100 % ethanol	19437
xylene	19437
100 % ethanol	19448
normotonic phosphate	19488
saline -LRB- pH = 7.4 -RRB-	19518
saline	19518
pH	19526
7.4	19529
0.3 % Triton-X	19545
Chem Supply	19560
SA	19573
Australia	19577
a 30 min pre-incubation	19595
phosphate buffered saline -- Triton-X solution containing 10 % goat serum	19623
phosphate	19623
saline -- Triton-X solution containing 10 % goat serum	19642
saline	19642
Triton-X solution containing 10 % goat serum	19649
Triton-X solution	19649
10 % goat serum	19678
the sections	19694
the primary antibody for 24 h	19727
the primary antibody	19727
24 h	19752
4 °C	19760
The sections	19766
phosphate	19799
saline	19818
Alexa Fluor 568-conjugated goat antimouse	19844
secondary antibody -LRB- 1:500 ; Molecular Probes , Oregon , USA -RRB-	19886
secondary antibody	19886
1:500 ; Molecular Probes	19906
1:500	19906
Molecular Probes	19913
Oregon , USA	19931
Oregon	19931
USA	19939
Alexa Fluor 488-conjugated goat	19947
anti-rabbit secondary antibody -LRB- 1:500 ; Molecular Probes -RRB-	19979
anti-rabbit secondary antibody	19979
1:500 ; Molecular Probes	20011
1:500	20011
Molecular Probes	20018
2 h at room temperature	20040
2 h	20040
room temperature	20047
the sections	20074
bisbenzimide	20112
0.001 % , Hoechst 33258 , Invitrogen Pty. Ltd. , VIC , Australia	20126
0.001 %	20126
Hoechst 33258	20134
Invitrogen Pty. Ltd.	20149
VIC	20171
Australia	20176
20 min	20191
DAKO mounting medium	20223
DakoCytomation	20245
Dako North America Inc.	20261
CA , USA	20286
No staining	20296
the antibodies	20322
rat liver	20356
spleen tissue -LRB- β-tubulin III antibody specificity tests -RRB-	20370
spleen tissue	20370
β-tubulin III antibody specificity tests	20385
β-tubulin	20385
III antibody specificity tests	20395
normal spinal cord -LRB- GFP antibody specificity tests -RRB-	20428
normal spinal cord	20428
GFP antibody specificity tests	20448
unlabelled spinal cord tissue -LRB- secondary antibody specificity tests -RRB-	20483
unlabelled spinal cord tissue	20483
secondary antibody specificity tests	20514
The tissue	20553
a fluorescent microscope -LRB- Olympus BX51 + DP70 -RRB-	20584
a fluorescent microscope	20584
Olympus BX51 + DP70	20610
Olympus BX51	20610
DP70	20623
2.10	20630
Histochemistry	20636
NADPH-diaphorase NADPH-diaphorase staining of sympathetic preganglionic neurons	20655
NADPH-diaphorase NADPH-diaphorase staining	20655
sympathetic preganglionic neurons	20701
the spinal cords	20754
the animals included in the functional experiments and the 6 intact animals	20774
the animals	20774
the functional experiments and the 6 intact animals	20798
the functional experiments	20798
the 6 intact animals	20829
The NADPHdiaphorase staining	20851
a standard protocol -LRB- Carrive and Paxinos , 1994	20908
a standard protocol -LRB- Carrive and Paxinos	20908
a standard protocol	20908
Paxinos	20941
1994	20950
Horizontal spinal cord sections	20957
phosphate	21004
saline for 1 h	21023
saline	21023
1 h	21034
0.05 % solution	21055
NADPH	21073
NADPH , Sigma-Aldrich Pty. Ltd. , NSW , Australia	21088
NADPH	21088
Sigma-Aldrich Pty. Ltd.	21095
NSW	21120
Australia	21125
0.0125 % nitroblue tetrazolium -LRB- Sigma Chemical Co. , MO , USA -RRB-	21137
0.0125 %	21137
nitroblue tetrazolium -LRB- Sigma Chemical Co. , MO , USA -RRB-	21145
nitroblue tetrazolium	21145
Sigma Chemical Co.	21168
MO	21188
USA	21192
0.5 % Triton-X in phosphate buffer -LRB- pH = 7.4 -RRB-	21201
0.5 % Triton-X	21201
phosphate buffer -LRB- pH = 7.4 -RRB-	21218
phosphate buffer	21218
pH	21236
7.4	21239
The tissue	21245
2 h at 37 °C	21280
2 h	21280
37 °C	21287
room temperature for 4 h	21310
room temperature	21310
4 h	21331
The reaction	21336
rinses in phosphate buffer and distilled water	21367
rinses	21367
phosphate buffer and distilled water	21377
phosphate buffer	21377
distilled water	21398
The sections	21415
overnight , cleared in 100 % ethanol for 4 -- 6 h ,	21443
overnight	21443
100 % ethanol for 4 -- 6 h	21465
100 % ethanol for 4	21465
100 % ethanol	21465
4	21482
6 h	21484
DAKO	21502
a light microscope -LRB- Olympus BX51 + DP70 -RRB-	21527
a light microscope	21527
Olympus BX51 + DP70	21547
Olympus BX51	21547
DP70	21560
2.11	21567
Morphometric analysis of sympathetic preganglionic neurons	21573
Morphometric analysis	21573
sympathetic preganglionic neurons	21598
sympathetic preganglionic neurons in the injured spinal cords	21658
sympathetic preganglionic neurons	21658
the injured spinal cords	21695
Krassioukov and Weaver -LRB- 1996 -RRB-	21750
Krassioukov and Weaver	21750
1996	21774
a researcher blind to the treatment	21783
a researcher	21783
the treatment	21805
each animal , 2	21823
each animal	21823
2	21836
3 horizontal sections through the intermediolateral column	21838
3 horizontal sections	21838
the intermediolateral column	21868
and 9 -- 10 neurons located rostral -LRB- T2 -- T3 -RRB- and 9	21911
and 9	21911
10 neurons located rostral -LRB- T2 -- T3 -RRB- and 9	21917
10 neurons located rostral -LRB- T2 -- T3 -RRB-	21917
10 neurons located rostral	21917
10 neurons	21917
T2 -- T3	21945
T2	21945
T3	21948
9	21956
10 neurons located caudal -LRB- T5 -- T6 -RRB- to the injury	21958
10 neurons located caudal -LRB- T5 -- T6 -RRB-	21958
10 neurons located caudal	21958
10 neurons	21958
T5 -- T6	21985
T5	21985
T6	21988
the injury	21995
ImageJ software -LRB- Wayne Rasband , National Institutes of Health , USA -RRB-	22026
ImageJ software	22026
Wayne Rasband , National Institutes of Health , USA	22043
Wayne Rasband	22043
National Institutes of Health	22058
National Institutes	22058
Health	22081
USA	22089
Each cell 's morphometric features	22095
Each cell 's	22095
one 35 μm thick horizontal section	22150
one 35 μm	22150
Only cells with clearly distinguishable perikarya and dendritic trees	22186
Only cells	22186
clearly distinguishable perikarya and dendritic trees	22202
clearly distinguishable perikarya	22202
dendritic trees	22240
The examined neurons	22271
the criteria	22302
the nucleus intermediolateralis pars principalis and pars funicularis	22331
2 segments from the injury site	22412
2 segments	22412
the injury site	22428
both left and right intermediolateral columns -LRB- Fig. 2 -RRB-	22475
both left and right intermediolateral columns	22475
Fig. 2	22522
Three morphological features	22531
: area of soma , overall length of all visible processes	22573
area of soma	22575
area	22575
soma	22583
overall length of all visible processes	22589
overall length	22589
all visible processes	22607
number of primary dendrites	22633
number	22633
primary dendrites	22643
The morphological features	22662
OECtreated , control and intact animals	22711
OECtreated	22711
control	22723
intact animals	22735
2.12	22751
Survival analysis of the transplanted cells	22757
Survival analysis	22757
the transplanted cells	22778
Spinal cords	22801
9 weeks -LRB- rats in the functional study -RRB-	22827
9 weeks	22827
rats in the functional study	22836
rats	22836
the functional study	22844
7 , 11 , 23 and 30 days post-injury	22880
7	22880
11	22883
23	22887
30 days post-injury	22894
rats in the cell survival study	22915
rats	22915
the cell survival study	22923
the presence of GFP-labelledOEC transplants	22965
the presence	22965
GFP-labelledOEC transplants	22981
Unstained sections as well as sections labelled with antibody against GFP	23010
Unstained sections as well as sections	23010
Unstained sections	23010
sections	23040
antibody against GFP	23063
antibody	23063
GFP	23080
DAKO and the GFP	23102
DAKO	23102
the GFP	23111
Alexa Fluor 488	23123
a fluorescent microscope -LRB- Olympus BX51 + DP70 -RRB-	23160
a fluorescent microscope	23160
Olympus BX51 + DP70	23186
Olympus BX51	23186
DP70	23199
2.13	23206
Statistical analysis Data	23212
mean ± SEM	23266
Software packages SPSS 16.0 and 17.0 for Windows	23276
Software packages	23276
SPSS 16.0 and 17.0 for Windows	23294
SPSS 16.0 and 17.0	23294
Windows	23317
SPSS Inc.	23326
Illinois	23337
USA	23347
all statistical analyses	23366
Effects	23392
p	23431
A one-way repeatedmeasures analysis of variance -LRB- ANOVA -RRB-	23439
A one-way repeatedmeasures analysis of variance	23439
A one-way repeatedmeasures analysis	23439
variance	23478
ANOVA	23488
comparemaxMAP , minHR and T50MAP between the OEC-treated and control groups	23506
comparemaxMAP , minHR and T50MAP	23506
the OEC-treated and control groups	23546
the period following SCI	23586
the period	23586
SCI	23607
The repeated measure	23612
time	23637
byweeks	23655
3 -- 8 after SCI	23663
3 -- 8	23663
SCI	23673
Relative changes	23678
andHR during autonomic dysreflexia	23701
andHR	23701
autonomic dysreflexia	23714
weeks	23750
3 -- 8	23756
a repeated measures ANOVA	23784
a repeated measures	23784
ANOVA	23804
time represented in seconds	23816
time	23816
seconds	23836
addition	23848
baseline MAP , baseline HR , peak MAP , peak HR and T50MAP	23858
baseline MAP	23858
baseline HR	23872
peak MAP	23885
peak HR	23895
T50MAP	23907
fromthe	23936
responses of the OECtreated and control groups	23953
responses	23953
the OECtreated and control groups	23966
unpaired t-tests	24020
Paired t-tests	24038
baseline MAP and baseline HR recorded prior to injury vs. values	24082
baseline MAP and baseline HR	24082
injury vs. values	24129
injury	24129
values	24140
weeks	24161
3 -- 8 post-injury	24167
3 -- 8	24167
Comparison	24184
morphometric features	24198
sympathetic preganglionic neurons rostral and caudal	24223
the injury in the OEC-treated , control and intact animals	24279
the injury	24279
the OEC-treated , control and intact animals	24293
control	24310
a linear mixed model -LRB- MIXED , SPSS 16.0 -RRB-	24358
a linear mixed model	24358
MIXED	24380
SPSS 16.0	24387
restricted maximum likelihood algorithm	24405
fixed and random effects	24457
Cnaan	24483
et al. , 1997 ; Verbeke andMolenberghs , 1997	24489
et al.	24489
1997 ; Verbeke andMolenberghs	24497
1997	24497
Verbeke andMolenberghs	24503
1997	24527
This model	24534
it	24559
a more rigorous test than ANOVA	24565
a more rigorous test	24565
ANOVA	24591
multiple measurements	24615
the same variable	24640
individual subjects -LRB- Khan et al. , 2006 ; Santovena et al. , 2007 -RRB-	24661
individual subjects	24661
Khan	24682
et al. , 2006 ; Santovena et al. , 2007	24687
et al.	24687
2006 ; Santovena et al.	24695
2006	24695
Santovena et al.	24701
Santovena	24701
et al.	24711
2007	24719
The effects of treatment and position	24726
The effects	24726
treatment and position	24741
the subject effect	24790
The model used	24817
The model	24817
-LRB- mathematical equation -RRB-	24861
yijkl	24891
the value	24900
a morphometric feature	24913
soma size , summed dendritic length or number of primary dendrites	24937
soma size , summed dendritic length	24937
soma size	24937
summed dendritic length	24948
number of primary dendrites	24975
number	24975
primary dendrites	24985
sympathetic preganglionic neuron l	25007
sympathetic preganglionic neuron	25007
l	25040
position j -LRB- rostral or caudal to SCI -RRB-	25053
position j	25053
rostral or caudal to SCI	25065
rostral or caudal	25065
SCI	25086
animal k that received treatment i	25094
animal k	25094
treatment	25117
i	25127
OECs , control or intact	25130
OECs	25130
control	25136
intact	25147
μ	25156
an overall mean of all values	25161
an overall mean	25161
all values	25180
τi	25192
the i-th treatment effect	25198
πj	25225
the effect at the j-th position	25231
the effect	25231
the j-th position	25245
τπ	25268
ij	25271
the joint effect -LRB- interaction -RRB- of position j	25277
the joint effect -LRB- interaction -RRB-	25277
the joint effect	25277
interaction	25295
position j	25311
treatment	25326
ak	25339
the k-th subject -LRB- animal -RRB- effect and εijkl the residual term	25353
the k-th subject -LRB- animal -RRB- effect	25353
the k-th subject	25353
animal	25371
effect	25379
εijkl the residual term	25390
εijkl	25390
the residual term	25396
σ2	25415
the residual variance and σp 2 the subject variance component	25421
the residual variance	25421
σp 2 the subject variance component	25447
σp 2	25447
the subject variance component	25452
Constant correlation	25484
all pairs of measurements on the same animal	25521
all pairs	25521
measurements on the same animal	25534
measurements	25534
the same animal	25550
Post-hoc comparisons	25567
unpaired t-test -LRB- position effect -RRB-	25603
unpaired t-test	25603
position effect	25620
unpaired t-test	25641
Bonferroni correction	25662
group effect in rostral or caudal neurons	25685
group effect	25685
rostral or caudal neurons	25701
Results	25733
1	25746
Balloon	25749
colorectal distension	25772
The lower part of the balloon	25795
The lower part	25795
the balloon	25813
located 1 cm	25829
1	25837
the anal opening -LRB- indicated by white bar -RRB-	25850
the anal opening	25850
white bar	25881
Graphs	25893
balloon diameter , internal pressure and volume	25912
balloon diameter	25912
internal pressure	25930
volume	25952
inflation	25966
Fig. 2 .	25978
Fig.	25978
2	25983
Examples	25986
sympathetic preganglionic neurons and their measured morphometric features	25998
sympathetic preganglionic neurons	25998
their measured morphometric features	26036
A , longitudinal section through an injured spinal cord	26074
, longitudinal section through an injured spinal cord	26075
, longitudinal section	26075
an injured spinal cord	26106
NADPHdiaphorase	26141
Sympathetic preganglionic neurons	26158
the intermediolateral columns -LRB- arrowheads -RRB-	26195
the intermediolateral columns	26195
arrowheads	26226
the lateral aspects of the grey matter rostral and caudal	26254
the lateral aspects	26254
the grey matter rostral and caudal	26277
the grey matter rostral	26277
caudal	26305
the lesion site	26315
Example	26332
measurement	26343
overall dendritic length -LRB- B , dashed line -RRB-	26358
overall dendritic length	26358
B , dashed line	26384
B	26384
line	26394
cross-sectional area of the soma -LRB- C , dashed area -RRB- for one neuron	26404
cross-sectional area	26404
the soma -LRB- C , dashed area -RRB- for one neuron	26428
the soma -LRB- C , dashed area -RRB-	26428
the soma	26428
C , dashed area	26438
C	26438
area	26448
one neuron	26458
Fig. 3 .	26471
Fig.	26471
3	26476
MinHR -LRB- A -RRB- and maxMAP -LRB- B -RRB-	26479
MinHR -LRB- A -RRB-	26479
MinHR	26479
A	26486
maxMAP -LRB- B -RRB-	26493
maxMAP	26493
B	26501
colorectal distension between weeks 3 and 8 following SCI	26516
colorectal distension	26516
weeks 3 and 8 following SCI	26546
weeks 3 and 8	26546
SCI	26570
No significant effect of OEC treatment	26575
No significant effect	26575
OEC treatment	26600
p > 0.5 , repeated measures ANOVA	26625
p	26625
> 0.5 ,	26626
> 0.5	26626
>	26626
0.5	26627
repeated measures ANOVA	26632
repeated measures	26632
ANOVA	26650
Fig. 4 .	26659
Fig.	26659
4	26664
Relative changes	26667
HR -LRB- A -RRB- and MAP -LRB- B -RRB- during colorectal distension	26687
HR -LRB- A -RRB-	26687
HR	26687
A	26691
MAP -LRB- B -RRB- during colorectal distension	26698
MAP -LRB- B -RRB-	26698
MAP	26698
B	26703
colorectal distension	26713
duration	26736
` CRD ' and bar	26758
inflation	26780
sustained distension	26791
deflation periods	26816
Graphs	26836
averages of weeks 3 -- 8	26853
averages	26853
weeks 3 -- 8	26865
weeks	26865
3 -- 8	26871
B	26876
peak MAP and T50MAP values for each group	26884
peak MAP and T50MAP values	26884
each group	26915
The MAP response	26927
the groups -LRB- p = 0.03 , repeated measures ANOVA -RRB-	26975
the groups	26975
p = 0.03 , repeated measures ANOVA	26987
p = 0.03	26987
p	26987
0.03	26989
measures	27004
ANOVA	27013
a shorter T50MAP	27025
the OEC-treated group	27045
the control group -LRB- p = 0.03 ; t-test -RRB-	27079
the control group	27079
p	27098
= 0.03 ; t-test	27099
= 0.03	27099
t-test	27106
Fig. 5 .	27116
Fig.	27116
5	27121
T50MAP by week .	27124
T50MAP	27124
week	27134
T50MAP	27149
the OEC-treated group	27185
the control group -LRB- p = 0.02 , repeated measures ANOVA -RRB-	27215
the control group	27215
p = 0.02 , repeated measures ANOVA	27234
p	27234
0.02 , repeated measures ANOVA	27236
0.02	27236
measures	27251
ANOVA	27260
Fig. 6 .	27269
Fig.	27269
6	27274
Survival of transplanted OECs -LRB- bold arrows -RRB- in the host spinal cord .	27277
Survival	27277
transplanted OECs -LRB- bold arrows -RRB- in the host spinal cord	27289
transplanted OECs -LRB- bold arrows -RRB-	27289
transplanted OECs	27289
bold arrows	27308
the host spinal cord	27324
Images	27346
the Gelfoam area	27358
7 -LRB- A -RRB- , 11 -LRB- B -RRB- , 23 -LRB- C -RRB- and 30 -LRB- D -RRB- days	27378
7 -LRB- A -RRB-	27378
11 -LRB- B -RRB-	27385
23 -LRB- C -RRB-	27393
30 -LRB- D -RRB- days	27404
30 -LRB- D -RRB-	27404
days	27411
None of the transplanted cells	27438
None	27438
the transplanted cells	27446
30 days	27482
E , the rostral border between the host spinal cord tissue and Gelfoam block	27512
E	27512
the rostral border between the host spinal cord tissue and Gelfoam block	27515
the rostral border	27515
the host spinal cord tissue and Gelfoam block	27542
the host spinal cord tissue	27542
Gelfoam block	27574
GFP-labelled OECs -LRB- green -RRB-	27607
GFP-labelled OECs	27607
11 days	27636
β-tubulin III-positive neuronal processes -LRB- red , thin arrows -RRB-	27671
β-tubulin III-positive neuronal processes	27671
β-tubulin	27671
III-positive neuronal processes	27681
red , thin arrows	27714
red	27714
thin arrows	27719
the Gelfoam in proximity	27751
the Gelfoam	27751
proximity	27766
OECs	27779
no fibres bridging the lesion	27794
no fibres	27794
the lesion	27813
F	27836
the control group	27842
a similar picture of β-tubulin III-positive fibre ingrowth	27861
a similar picture	27861
β-tubulin III-positive fibre ingrowth	27882
Scale	27934
100 μm	27944
Fig. 7 .	27953
Fig.	27953
7	27958
Morphometric features	27961
sympathetic preganglionic neurons	27986
intact animals	28023
9 weeks following SCI in control and OEC-treated animals	28045
9 weeks	28045
SCI in control and OEC-treated animals	28063
SCI	28063
control and OEC-treated animals	28070
A , example of sympathetic preganglionic neurons	28103
example	28106
sympathetic preganglionic	28117
NADPH-diaphorase	28163
a horizontal section	28183
nucleus intermediolateralis of an intact animal	28212
nucleus intermediolateralis	28212
an intact animal	28243
Soma	28261
size -LRB- B -RRB-	28266
size	28266
B	28272
overall dendritic length -LRB- C -RRB-	28276
overall dendritic length	28276
C	28302
number	28309
primary dendrites -LRB- D -RRB-	28319
primary dendrites	28319
D	28338
the preganglionic neurons rostral and caudal	28344
the injury site	28392
the intact animals at corresponding levels -- T2 -- 3 and T5 -- 6	28412
the intact animals	28412
corresponding levels -- T2 -- 3 and T5 -- 6	28434
corresponding levels	28434
T2	28457
3 and T5	28460
3	28460
T5	28466
6	28469
all analysed features	28477
all	28477
features	28490
a significant interaction effect between position and group	28500
a significant interaction effect	28500
position and group	28541
p	28571
≤ 0.01 ; linear mixed model	28572
≤ 0.01	28572
linear mixed model	28579
Graphs	28600
differences	28612
post-hoc analyses	28637
position effect	28656
# p < 0.05 , t-test	28673
# p < 0.05	28673
# p <	28673
0.05	28676
t-test	28682
group effect	28690
p < 0.05	28705
p <	28705
p	28705
0.05	28707
t-test with Bonferroni correction	28713
t-test	28713
Bonferroni correction	28725
3.1	28749
Effect of OEC transplantation on cardiovascular parameters at rest	28754
Effect	28754
OEC transplantation on cardiovascular parameters at rest	28764
OEC transplantation	28764
cardiovascular parameters at rest	28787
cardiovascular parameters	28787
rest	28816
our lab -LRB- Laird et al. , 2006 -RRB-	28847
our lab	28847
Laird	28856
et al. , 2006	28862
et al.	28862
2006	28870
others -LRB- Krassioukov and Weaver , 1996 -RRB-	28880
others	28880
Krassioukov and Weaver , 1996	28888
Krassioukov	28888
Weaver , 1996	28904
Weaver	28904
1996	28912
transection	28919
a reduction	28938
MAP and an increase	28953
MAP	28953
an increase	28961
HR	28976
Baseline MAP values	28980
intact animals	29004
OEC-treated group : 100 ± 2 mmHg ; control group : 102 ± 1 mmHg	29020
OEC-treated group	29020
100 ± 2 mmHg ; control group : 102 ± 1 mmHg	29039
100 ± 2 mmHg	29039
100 ±	29039
2 mmHg	29043
control group	29051
control	29051
group	29059
102 ± 1 mmHg	29066
102 ±	29066
1 mmHg	29070
approximately 17mmHg	29086
week 3	29110
this new level for weeks	29140
this new level	29140
weeks	29159
3 -- 8	29165
OEC-treated group	29170
weeks 3	29189
weeks	29189
3	29195
8 average	29197
8	29197
average	29199
84 ± 5 mmHg	29208
84	29208
5 mmHg	29211
control values , weeks 3	29219
control values	29219
weeks 3	29235
weeks	29235
3	29241
8 average	29243
8	29243
average	29245
84 ± 4 mmHg	29254
84	29254
4 mmHg	29257
Heart rate	29266
intact values	29292
OEC-treated group : 319 ± 7 bpm ; control group : 336 ± 12 bpm	29307
OEC-treated group	29307
319 ± 7 bpm ; control group : 336 ± 12 bpm	29326
319 ± 7 bpm	29326
319 ±	29326
7 bpm	29331
control group	29338
control	29338
group	29346
336 ± 12 bpm	29353
336	29353
12 bpm	29357
over 400 bpm	29368
week 3	29384
elevated	29404
week 8	29418
OEC-treated group	29426
weeks 3	29445
weeks	29445
3	29451
8 average : 454 ± 18 bpm	29453
8 average : 454 ±	29453
8 average	29453
454	29464
18 bpm	29468
control group weeks 3	29476
control group weeks	29476
3	29496
8 average : 428 ± 17 bpm	29498
8 average : 428 ±	29498
8 average	29498
428	29509
17 bpm	29513
The injury effect on both MAP and HR	29521
The injury effect	29521
both MAP and HR	29542
p < 0.001 , t -LRB- 11 -RRB-	29582
p	29582
<	29583
0.001 , t -LRB- 11 -RRB-	29584
0.001	29584
t -LRB- 11 -RRB-	29591
t	29591
11	29593
6.7 ; paired t-tests	29597
6.7	29597
paired t-tests	29602
There	29619
no group effect	29629
OECtreated and control animals	29653
weeks 3 -- 8	29688
weeks	29688
3 -- 8	29694
; p ≥ 0.3 , t -LRB- 11 -RRB- ≤ 1.02 ; t-tests	29714
; p ≥ 0.3 , t -LRB- 11 -RRB- ≤ 1.02	29714
p ≥ 0.3	29716
p	29716
≥ 0.3	29717
t -LRB- 11 -RRB- ≤ 1.02	29723
t	29723
11	29725
≤ 1.02	29728
t-tests	29735
3.2	29745
Effect of OEC transplantation on autonomic dysreflexia	29750
Effect	29750
OEC transplantation on autonomic dysreflexia	29760
OEC transplantation	29760
autonomic dysreflexia	29783
autonomic dysreflexia	29821
the experiment -LRB- i.e. at weeks 3 -- 8 post-injury ; Fig. 3 -RRB-	29866
the experiment	29866
i.e. at weeks 3 -- 8 post-injury ; Fig. 3	29882
i.e.	29882
weeks 3 -- 8 post-injury ; Fig. 3	29890
weeks 3 -- 8 post-injury	29890
weeks 3	29890
Fig. 3	29913
The maxMAP and minHR	29922
+30 mm Hg and − 60 bpm	29965
+30 mm Hg	29965
− 60 bpm	29979
Overall maxMAP and minHR	30002
Overall maxMAP	30002
minHR	30021
the groups	30054
p > 0.5 , F -LRB- 1,11 -RRB- ≤ 0.36 ; repeated measures ANOVA	30066
p	30066
> 0.5 , F -LRB- 1,11 -RRB-	30067
> 0.5 , F	30067
>	30067
0.5 , F	30068
0.5	30068
F	30073
1,11	30075
0.36	30081
measures	30096
ANOVA	30105
Time courses of theMAP andHR responseswere	30113
Time courses	30113
theMAP andHR responseswere	30129
overweeks 3 -- 8 and compared between the groups -LRB- Fig. 4 -RRB-	30165
overweeks 3	30165
overweeks	30165
3	30175
8	30177
the groups -LRB- Fig. 4 -RRB-	30200
the groups	30200
Fig. 4	30212
colorectal distension	30237
a rapid rise	30268
MAP accompanied by a drop in HR in both OEC-treated and control groups	30284
MAP	30284
a drop in HR	30303
a drop	30303
HR	30313
both OEC-treated and control groups	30319
OEC-treated	30324
control groups	30340
these episodes	30363
we	30379
any significant difference	30398
the peak HR -LRB- p = 0.4 , t -LRB- 11 -RRB- = 0.83 ; t-test -RRB-	30435
the peak HR	30435
p = 0.4 , t -LRB- 11 -RRB- = 0.83 ; t-test	30448
p	30448
= 0.4 , t -LRB- 11 -RRB- = 0.83 ; t-test	30449
= 0.4 , t -LRB- 11 -RRB- = 0.83	30449
= 0.4 , t -LRB- 11 -RRB-	30449
= 0.4 , t	30449
0.4	30450
11	30457
0.83	30462
t-test	30468
the overall HR response	30479
p = 0.5 , F -LRB- 1,11 -RRB- = 0.38 ; repeated measures ANOVA	30504
p	30504
= 0.5 , F -LRB- 1,11 -RRB-	30505
= 0.5 , F	30505
0.5	30506
1,11	30513
= 0.38 ; repeated measures ANOVA	30518
= 0.38	30518
measures	30534
ANOVA	30543
the two groups	30558
contrast	30577
OEC treatment	30587
an effect on the change	30605
an effect	30605
the change	30618
MAP , which was confirmed by a repeated measures	30632
MAP	30632
a repeated measures	30660
ANOVA -LRB- p = 0.03 , F -LRB- 1,11 -RRB- = 5.77 -RRB-	30680
ANOVA	30680
p = 0.03 , F -LRB- 1,11 -RRB- = 5.77	30687
p	30687
= 0.03 , F -LRB- 1,11 -RRB- = 5.77	30688
= 0.03 , F -LRB- 1,11 -RRB-	30688
= 0.03 , F	30688
0.03	30689
1,11	30697
5.77	30703
Fig. 4 B	30728
peak changes in MAP	30738
peak changes	30738
MAP	30754
lower	30767
the OEC-treated animals	30776
the controls -LRB- +36 ± 2 mm Hg vs. +40 ± 2 mm Hg , respectively -RRB-	30812
the controls	30812
+36 ± 2 mm Hg vs. +40 ± 2 mm Hg , respectively	30826
+36 ±	30826
2 mm Hg vs. +40 ± 2 mm Hg , respectively	30830
2 mm Hg	30830
+40 ± 2 mm Hg , respectively	30842
+40 ±	30842
2 mm Hg	30846
this difference	30874
p = 0.4 , t -LRB- 11 -RRB- = 0.89 ; t-test	30925
p	30925
= 0.4 , t -LRB- 11 -RRB- = 0.89 ; t-test	30926
= 0.4 , t -LRB- 11 -RRB- = 0.89	30926
= 0.4 , t -LRB- 11 -RRB-	30926
= 0.4 , t	30926
0.4	30927
11	30934
t-test	30944
itwas apparent that the recovery from hypertension	30962
itwas	30962
the recovery from hypertension	30982
the recovery	30982
hypertension	31000
the OEC-treated animals	31027
the controls	31059
This faster recoverywas confirmed by a comparison of	31073
This faster recoverywas	31073
a comparison of	31110
a comparison	31110
T50MAP	31135
the two groups	31150
Fig.	31166
4 B	31171
78 ± 5 s	31176
78	31176
5 s	31179
the OEC-treated group	31186
100 ± 7 s in the control group ; p = 0.03 , t -LRB- 11 -RRB- = 2.51	31212
7 s in the control group	31216
7 s	31216
the control group	31223
p = 0.03	31242
p	31242
0.03	31244
t -LRB- 11 -RRB- = 2.51	31250
t -LRB- 11 -RRB-	31250
t	31250
11	31252
2.51	31256
t-test	31262
average	31274
T50MAP	31283
22 s -LRB- 95 % confidence interval : 3 -- 42 s -RRB- , i.e.	31307
22 s -LRB- 95 % confidence interval : 3 -- 42 s -RRB-	31307
22 s	31307
95 % confidence interval	31313
95 %	31313
confidence interval	31317
3 -- 42 s	31338
3	31338
42 s	31342
i.e.	31349
22 %	31357
The overall duration of dysreflexic hypertension in the OEC-treated animals	31362
The overall duration	31362
dysreflexic hypertension in the OEC-treated animals	31386
dysreflexic hypertension	31386
the OEC-treated animals	31414
approximately 2 min	31442
i.e.	31471
25 %	31487
the control group -LRB- 7.5 min vs. 5.5 min , respectively -RRB-	31504
the control group	31504
7.5 min vs. 5.5 min , respectively	31523
7.5 min vs. 5.5 min	31523
7.5 min	31523
5.5 min	31535
Fig. 5	31559
the difference in T50MAP	31577
the difference	31577
T50MAP	31595
the study	31626
week 6	31646
the recovery time in both groups	31659
the recovery time	31659
both groups	31680
This observation	31708
a repeated measures	31744
ANOVA -LRB- p = 0.02 , F -LRB- 1,11 -RRB- = 7.95 -RRB-	31764
ANOVA	31764
p = 0.02 , F -LRB- 1,11 -RRB- = 7.95	31771
p	31771
= 0.02 , F -LRB- 1,11 -RRB- = 7.95	31772
= 0.02 , F -LRB- 1,11 -RRB-	31772
= 0.02 , F	31772
0.02	31773
1,11	31781
7.95	31787
3.3	31794
In vivo survival of transplanted OECs Spinal cord tissue	31799
In vivo survival	31799
transplanted OECs Spinal cord tissue	31819
transplanted OECs	31819
Spinal cord tissue	31837
an antibody against humanised R. reniformis GFP	31874
an antibody	31874
humanised R. reniformis GFP	31894
survival of the GFP-positive OECs	31934
survival	31934
the GFP-positive OECs	31946
No OECs	31969
the spinal cords collected 9 weeks post-injury -LRB- not illustrated -RRB-	31995
the spinal cords	31995
9 weeks post-injury -LRB- not illustrated -RRB-	32022
9 weeks post-injury	32022
Closer analysis ofOEC survival , undertaken in animals of the survival study ,	32061
Closer analysis ofOEC survival	32061
animals of the survival study	32107
animals	32107
the survival study	32118
the transplanted cells	32150
the injury for 3 weeks following transplantation -LRB- Fig. 6 -RRB-	32189
the injury	32189
3 weeks following transplantation -LRB- Fig. 6 -RRB-	32204
3 weeks	32204
transplantation -LRB- Fig. 6 -RRB-	32222
transplantation	32222
Fig. 6	32239
all 6 spinal cords examined 7 days after transplantation	32251
all 6 spinal cords	32251
7 days	32279
transplantation	32292
the OECs	32309
high numbers	32334
They	32348
inner surfaces of the collagen matrix	32369
inner surfaces	32369
the collagen matrix	32387
a spindle-shaped morphology	32417
day 11	32449
the cells	32457
numerous	32472
the entire transplant in all 3 cords examined	32511
the entire transplant	32511
all 3 cords examined	32536
all 3 cords	32536
day 23	32561
the Gelfoam	32569
Only small numbers of OECs surviving deeply in the Gelfoam	32607
Only small numbers	32607
OECs surviving deeply in the Gelfoam	32629
OECs	32629
the Gelfoam	32654
2	32689
3 spinal cords	32698
The OECswere not seen in any of the 6 spinal cords	32714
The OECswere	32714
any of the 6 spinal cords	32739
any	32739
the 6 spinal cords	32746
30 days	32774
transplantation	32788
the injury site	32822
the OECs	32839
the Gelfoam	32885
only occasional migration of the cells into the host spinal cord	32898
only occasional migration	32898
the cells into the host spinal cord	32927
the cells	32927
the host spinal cord	32942
7 days	32972
Eleven days	33001
post-injury , sparse areas	33013
β-tubulin III-positive fibres entering into the Gelfoam block close to the OECs	33044
β-tubulin III-positive fibres	33044
the Gelfoam block close	33088
the OECs	33115
Fig. 6 E	33139
Fig.	33139
6 E	33144
some areas	33153
the axons	33165
several hundred micrometers	33198
the injury site	33231
no fibres bridging the lesion	33257
no fibres	33257
the lesion	33276
the β-tubulin III-positive fibre ingrowth	33317
the β-tubulin	33317
III-positive fibre ingrowth	33331
the OEC-treated and control groups -LRB- Fig. 6 F -RRB-	33392
the OEC-treated and control groups	33392
Fig. 6 F	33428
Fig.	33428
6 F	33433
The transplant integrated well and at some sites	33439
The transplant	33439
some sites	33477
the host nervous tissue	33508
later stages -LRB- days 23 and 30 after transplantation -RRB-	33536
later stages	33536
days 23 and 30 after transplantation	33550
days 23 and 30	33550
transplantation	33571
the border between the collagen matrix and the host tissue	33589
the border	33589
the collagen matrix and the host tissue	33608
the collagen matrix	33608
the host tissue	33632
a dense scar	33671
3.4	33685
Morphometric analysis of sympathetic preganglionic neurons	33690
Morphometric analysis	33690
sympathetic preganglionic neurons	33715
Morphometric features	33749
NADPH-diaphorase-stained sympathetic preganglionic neurons	33774
9 weeks following SCI	33847
9 weeks	33847
SCI	33865
completion of functional assessments	33875
completion	33875
functional assessments	33889
Soma size	33913
overall dendritic length	33924
number	33953
primary dendrites	33963
sympathetic preganglionic neurons	33984
the intermediolateral columns , rostral and caudal	34021
the spinal cord transection site	34074
the OEC-treated , control and intact groups	34130
a 3 × 2 -LRB- group × position -RRB- linear mixed model analysis	34179
3 ×	34181
2	34183
group × position	34186
group	34186
× position	34191
each animal	34234
9 -- 10 neurons rostral and 9 -- 10 caudal to the injury , in 2 -- 3 sections	34247
9 -- 10 neurons rostral	34247
9	34247
10 neurons	34249
9 -- 10 caudal to the injury , in 2 -- 3 sections	34272
9	34272
10 caudal to the injury , in 2	34274
10 caudal	34274
the injury	34287
2	34302
3 sections	34304
summary of the number of analysed neurons	34334
summary	34334
the number of analysed neurons	34345
the number	34345
analysed neurons	34359
Fig. 7	34381
The analysis	34390
an interaction effect -LRB- group × position -RRB-	34410
an interaction effect	34410
group × position	34433
all 3 morphometric features -LRB- p ≤ 0.01 , F -LRB- 2,353 -RRB-	34452
all 3 morphometric features -LRB- p ≤ 0.01 , F	34452
3 morphometric features -LRB- p ≤ 0.01 ,	34456
3 morphometric features	34456
p ≤ 0.01	34481
p	34481
≤ 0.01	34482
2,353	34491
4.63 ; linear mixed model	34498
4.63	34498
linear mixed model	34504
Fig. 7	34543
injury	34551
an increase	34565
soma size	34580
p = 0.004 , t -LRB- 124 -RRB- = − 3.25 ; t-test with Bonferroni correction	34624
p	34624
= 0.004 , t -LRB- 124 -RRB- = − 3.25 ; t-test with Bonferroni correction	34625
= 0.004 , t -LRB- 124 -RRB- = − 3.25	34625
= 0.004 , t -LRB- 124 -RRB- = −	34625
= 0.004 , t -LRB- 124 -RRB-	34625
= 0.004 , t	34625
0.004	34626
124	34635
−	34640
3.25	34641
t-test with Bonferroni correction	34647
t-test	34647
Bonferroni correction	34659
injury	34692
no effect on dendritic length or numbers	34703
no effect	34703
dendritic length or numbers	34716
rostral	34754
caudal regions	34765
p > 0.3 , t -LRB- 124 -RRB- ≤ 1.56 ; t-tests with Bonferroni correction	34781
p	34781
> 0.3 , t -LRB- 124 -RRB- ≤ 1.56 ; t-tests with Bonferroni correction	34782
> 0.3 , t -LRB- 124 -RRB- ≤ 1.56	34782
>	34782
0.3 , t -LRB- 124 -RRB- ≤ 1.56	34783
0.3	34783
t	34788
124	34790
1.56	34795
t-tests with Bonferroni correction	34801
t-tests	34801
Bonferroni correction	34814
OEC treatment	34838
the injury effect	34867
soma size rostrally	34888
soma size	34888
p = 1.0 , t -LRB- 123 -RRB- = − 0.42 ; t-test with Bonferroni correction	34909
p	34909
= 1.0 , t -LRB- 123 -RRB- = − 0.42 ; t-test with Bonferroni correction	34910
= 1.0 , t -LRB- 123 -RRB- = − 0.42	34910
= 1.0 , t -LRB- 123 -RRB-	34910
= 1.0 , t	34910
1.0	34911
123	34918
− 0.42	34923
t-test with Bonferroni correction	34930
t-test	34930
Bonferroni correction	34942
this parameter	34991
caudal preganglionic neurons	35009
p = 0.03 , t -LRB- 128 -RRB- = 0.9 ; t-test with Bonferroni correction	35039
p	35039
= 0.03 , t -LRB- 128 -RRB- = 0.9 ; t-test with Bonferroni correction	35040
= 0.03 , t -LRB- 128 -RRB- = 0.9	35040
= 0.03 , t -LRB- 128 -RRB-	35040
= 0.03 , t	35040
0.03	35041
128	35049
0.9	35054
t-test with Bonferroni correction	35059
t-test	35059
Bonferroni correction	35071
Dendritic length	35095
OEC treatment	35142
p = 0.008 , t -LRB- 123 -RRB- = − 2.8 ; t-test with Bonferroni correction	35157
p	35157
= 0.008 , t -LRB- 123 -RRB- = − 2.8 ; t-test with Bonferroni correction	35158
= 0.008 , t -LRB- 123 -RRB- = − 2.8	35158
= 0.008 , t -LRB- 123 -RRB-	35158
= 0.008 , t	35158
0.008	35159
123	35168
− 2.8	35174
t-test with Bonferroni correction	35180
t-test	35180
Bonferroni correction	35192
no change	35224
p = 1.0 , t -LRB- 128 -RRB- = − 0.93 ; t-test with Bonferroni correction	35257
p	35257
= 1.0 , t -LRB- 128 -RRB- = − 0.93 ; t-test with Bonferroni correction	35258
= 1.0 , t -LRB- 128 -RRB- = − 0.93	35258
= 1.0 , t -LRB- 128 -RRB-	35258
= 1.0 , t	35258
1.0	35259
128	35266
− 0.93	35271
t-test with Bonferroni correction	35278
t-test	35278
Bonferroni correction	35290
OEC treatment	35314
the number	35343
primary dendrites in either location -LRB- p ≥ 0.1 , t -LRB- 123 -RRB-	35357
primary dendrites	35357
either location -LRB- p ≥ 0.1 , t -LRB- 123 -RRB-	35378
either location -LRB- p ≥ 0.1 , t	35378
either location -LRB- p ≥ 0.1 ,	35378
either location	35378
p ≥ 0.1	35395
p	35395
≥ 0.1	35396
123	35404
2.06 ; t-tests with Bonferroni correction	35410
2.06 ; t-tests	35410
2.06	35410
t-tests	35416
Bonferroni correction	35429
the position	35468
an effect on the morphology of preganglionic neurons	35485
an effect	35485
the morphology of preganglionic neurons	35498
the morphology	35498
preganglionic neurons	35516
the OEC-treated animals	35541
the OEC-treated group	35570
all morphometric features	35593
higher values	35626
rostral neurons	35643
those located caudally	35671
p ≤ 0.003 , t -LRB- 117 -RRB- ≥ 3.05 ; t-tests	35695
p	35695
≤ 0.003 , t -LRB- 117 -RRB- ≥ 3.05 ; t-tests	35696
≤ 0.003 , t -LRB- 117 -RRB- ≥ 3.05	35696
≤	35696
0.003 , t -LRB- 117 -RRB- ≥ 3.05	35697
0.003	35697
t	35704
117	35706
3.05	35712
t-tests	35718
Discussion	35732
We	35743
OEC transplants	35767
the duration of autonomic dysreflexia	35805
the duration	35805
autonomic dysreflexia	35821
colorectal distension	35853
they	35885
no effect on resting cardiovascular parameters	35894
no effect	35894
cardiovascular parameters	35915
We	35942
further	35950
OEC transplantation	35976
the morphology of sympathetic preganglionic neurons rostral and caudal	36004
the morphology	36004
sympathetic preganglionic neurons rostral and caudal	36022
the injury site 9 weeks following SCI	36078
the injury site	36078
9 weeks	36094
SCI	36112
the neurons rostral to the SCI	36117
the neurons rostral	36117
the SCI	36140
an increase	36155
total length of the dendritic processes , while the neurons caudal to the injury	36170
total length	36170
the dendritic processes , while the neurons caudal to the injury	36186
the dendritic processes	36186
the neurons	36217
the injury	36239
a decrease	36263
size of their somata	36277
size	36277
their somata	36285
4.1	36299
MAP and HR T4 transection	36312
a fall	36345
restingMAP and an increase	36355
restingMAP	36355
an increase	36370
HR	36385
others	36410
Krassioukov andWeaver	36418
1995a ; Laird et al. , 2006 ; Marsh andWeaver , 2004 ; Mayorov et al.	36441
1995a	36441
Laird et al. , 2006 ; Marsh andWeaver , 2004 ; Mayorov et al.	36448
Laird	36448
et al. , 2006 ; Marsh andWeaver , 2004 ; Mayorov et al.	36454
et al. , 2006	36454
et al.	36454
2006	36462
Marsh andWeaver , 2004	36467
Marsh andWeaver	36467
2004	36484
Mayorov et al.	36489
Mayorov	36489
et al.	36497
2001	36505
Both parameters	36512
their new values	36547
weeks 3 -- 8 post-injury	36568
weeks 3	36568
Some studies	36591
recovery	36615
MAP	36627
HR	36643
a few days	36654
injury -LRB- Marsh andWeaver , 2004 ; Mayorov et al. , 2001 -RRB-	36668
injury	36668
Marsh andWeaver , 2004 ; Mayorov et al. , 2001	36676
Marsh andWeaver	36676
2004 ; Mayorov et al.	36693
2004	36693
Mayorov et al.	36699
Mayorov	36699
et al.	36707
2001	36715
the type of injury	36764
the type	36764
injury	36776
the partial damage	36789
clip compression	36818
Marsh and Weaver -LRB- 2004 -RRB- and Mayorov et al -LRB- 2001 -RRB-	36844
Marsh and Weaver -LRB- 2004 -RRB-	36844
Marsh and Weaver	36844
2004	36862
Mayorov et al -LRB- 2001 -RRB-	36872
Mayorov	36872
et al -LRB- 2001 -RRB-	36880
et al	36880
2001	36887
better recovery	36903
complete transection -LRB- used here and by Laird et al -LRB- 2006 -RRB- -RRB-	36930
Laird	36969
et al -LRB- 2006 -RRB-	36975
et al	36975
2006	36982
4.2	36990
OEC survival and migration Wefound	36995
syngeneic OECs	37035
the transection site	37074
a Gelfoam block	37103
only 3 weeks	37133
transplantation	37152
This	37169
odds with many reports of long-term OEC survival , of at least 6 -- 12 weeks	37180
odds	37180
many reports of long-term OEC survival , of at least 6 --	37190
many reports	37190
long-term OEC survival	37206
at least 6	37233
12 weeks	37244
injection	37260
the cord	37275
Li et al. , 1998 ; Nash et al. , 2002 ; Ramon-Cueto et al. , 1998	37285
Li	37285
et al. , 1998 ; Nash et al. , 2002 ; Ramon-Cueto et al. , 1998	37288
et al. , 1998	37288
et al.	37288
1998	37296
Nash et al. , 2002	37302
Nash	37302
et al. , 2002	37307
et al.	37307
2002	37315
Ramon-Cueto et al. , 1998	37321
Ramon-Cueto	37321
et al. , 1998	37333
et al.	37333
1998	37341
One factor that differs	37348
the embedding of OECswithin Gelfoam	37380
the embedding	37380
OECswithin Gelfoam	37397
direct injection into cord tissue	37429
direct injection	37429
cord tissue	37451
It	37464
transplantation within a Gelfoamblockmay	37484
transplantation	37484
a Gelfoamblockmay	37507
poorer oxygenation and nutrient supply to the cells	37542
poorer oxygenation and nutrient supply	37542
the cells	37584
this	37595
other studies in our lab	37616
other studies	37616
our lab	37633
similarly prepared OECs	37647
cord injury	37675
cell survival	37694
9 weeks	37725
direct injection -LRB- Dr. Frank Cloutier , unpublished results -RRB-	37739
direct injection	37739
Dr. Frank Cloutier , unpublished results	37757
Dr. Frank Cloutier	37757
unpublished results	37777
the Gelfoam block	37814
a more aggressive immune response	37851
we	37895
this	37907
Gelfoam	37924
excessive tissue reaction or scarring	37966
excessive tissue reaction	37966
scarring	37995
Transplantation	38005
cells into the lesion site rather than to adjacent cord tissue	38024
cells	38024
the lesion site	38035
adjacent cord tissue	38066
survival	38112
A recent study by Pearse et al. -LRB- 2007 -RRB-	38122
A recent study by Pearse et al.	38122
A recent study by Pearse	38122
A recent study	38122
Pearse	38140
et al.	38147
2007	38155
a contusion injury and a delayed injection of cells	38168
a contusion injury	38168
a delayed injection of cells	38191
a delayed injection	38191
cells	38214
a better survival of OECs	38230
a better survival	38230
OECs	38251
the lesion area	38282
injections	38310
the lesion epicentre -LRB- 60 % vs. < 5 % at 9 weeks post-injection -RRB-	38326
the lesion epicentre	38326
60 % vs. < 5 % at 9 weeks post-injection	38348
60 %	38348
< 5 % at	38356
<	38356
5 %	38357
9 weeks	38363
Themany factors that may affect cell survival	38388
Themany factors	38388
cell survival	38420
Pearse	38456
et al. -LRB- 2007 -RRB-	38463
et al.	38463
2007	38471
the source of OECs -LRB- olfactory bulb vs. lamina propria -RRB-	38489
the source	38489
OECs -LRB- olfactory bulb vs. lamina propria -RRB-	38503
OECs	38503
olfactory bulb vs. lamina propria	38509
olfactory bulb	38509
lamina propria	38528
methods of cell preparation	38544
methods	38544
cell preparation	38555
the type of spinal cord injury	38573
the type	38573
spinal cord injury	38585
time of transplantation following the injury and the strain of animals used	38605
time	38605
transplantation following the injury and the strain of animals used	38613
transplantation	38613
the injury and the strain of animals used	38639
the injury	38639
the strain of animals used	38654
the strain	38654
animals used	38668
animals	38668
We	38682
a combination	38698
factors	38715
the aggressive environment	38732
the acute spinal cord -LRB- Bao and Liu , 2002 ; Woodhouse et al. , 2005 -RRB-	38762
the acute spinal cord	38762
Bao and Liu	38785
Bao	38785
Liu	38793
2002 ; Woodhouse et al. , 2005	38798
2002	38798
Woodhouse et al. , 2005	38804
Woodhouse	38804
et al. , 2005	38814
et al.	38814
2005	38822
the delivery of cells directly into the transection site	38829
the delivery	38829
cells directly into the transection site	38845
cells	38845
the transection site	38865
their insertion within Gelfoam	38890
their insertion	38890
Gelfoam	38913
the relatively rapid death seen here	38959
the relatively rapid death	38959
It	38997
theirmigratory ability	39031
previous studies	39060
our laboratory	39080
Deng	39096
et al. , 2006	39101
et al.	39101
2006	39109
others	39119
Lankford	39127
et al. , 2008 ; Ramon-Cueto et al. , 2000	39136
et al.	39136
2008 ; Ramon-Cueto et al.	39144
2008	39144
Ramon-Cueto et al.	39150
Ramon-Cueto	39150
et al.	39162
2000	39170
OECs injected directly into spinal cord tissue	39192
OECs	39192
spinal cord tissue	39220
considerable distances	39248
the limited survival and poor migration of the OECs	39279
the limited survival and poor migration	39279
the OECs	39322
the method of transplantation used in the present studies	39332
the method	39332
transplantation used in the present studies	39346
transplantation	39346
the present studies	39370
a long-term cell viability	39416
other paradigms	39453
cell transplantation	39472
a better cell engraftment	39504
direct injection of the transplant into the spinal cord	39539
direct injection	39539
the transplant into the spinal cord	39559
the transplant	39559
the spinal cord	39579
employed.However	39606
our data	39624
even the transitory presence of the OECs at the injury site	39646
even the transitory presence	39646
the OECs at the injury site	39678
the OECs	39678
the injury site	39690
long-term changes	39716
spinal cord morphology	39737
better recovery from autonomic dysreflexia which outlasted their survival	39776
better recovery	39776
autonomic dysreflexia	39797
their survival	39835
A similar phenomenon	39851
Guest	39893
et al.	39899
2008	39907
temporary OEC survival	39926
the injured spinal cord	39952
long-term improvement in the hind limb motor performance	39992
long-term improvement	39992
the hind limb motor performance	40017
4.3	40050
OECs and autonomic dysreflexia The present study	40055
OECs	40055
autonomic dysreflexia The present study	40064
autonomic dysreflexia	40064
The present study	40086
the first time	40117
the effect of OEC transplantation on the duration of autonomic dysreflexia	40132
the effect	40132
OEC transplantation on the duration of autonomic dysreflexia	40146
OEC transplantation	40146
the duration of autonomic dysreflexia	40169
the duration	40169
autonomic dysreflexia	40185
The faster recovery of the MAP in the OEC-treated group	40208
The faster recovery	40208
the MAP in the OEC-treated group	40231
the MAP	40231
the OEC-treated group	40242
a shortening of the dysreflexic episodes by approximately 2 min , or 25 %	40276
a shortening	40276
the dysreflexic episodes by approximately 2 min , or 25 %	40292
the dysreflexic episodes by approximately 2 min	40292
the dysreflexic episodes	40292
approximately 2 min	40320
25 %	40343
patients with high spinal cord injury	40372
patients	40372
high spinal cord injury	40386
dysreflexic hypertension -LRB- which can exceed 250/200 mm Hg -RRB-	40411
dysreflexic hypertension	40411
250/200 mm Hg	40454
serious consequences	40483
myocardial infarction , seizure , stroke and death	40513
Lindan et al. , 1980 ; Mathias and Frankel , 1999	40563
Lindan	40563
et al. , 1980 ; Mathias and Frankel , 1999	40570
et al. , 1980	40570
et al.	40570
1980	40578
Mathias and Frankel , 1999	40584
Mathias and Frankel	40584
1999	40605
any shortening of the duration of the hypertensive episodes	40622
any	40622
the duration of the hypertensive episodes	40640
the duration	40640
the hypertensive episodes	40656
a decreased risk of associated complications	40693
a decreased risk	40693
associated complications	40713
the evidence of functional improvement	40747
the evidence	40747
functional improvement	40763
the exact mechanismof the OEC effect	40787
the exact mechanismof	40787
the OEC effect	40809
It	40841
the cardiac baroreflex	40861
a role	40895
the faster recovery	40905
there	40929
no difference	40939
the bradycardic response between the OEC-treated and control animals	40956
the bradycardic response	40956
the OEC-treated and control animals	40989
the effect of OECs on the MAP response	41036
the effect	41036
OECs on the MAP response	41050
OECs	41050
the MAP response	41058
several minutes	41089
the heart rate	41111
baseline	41142
4.4	41152
SCI and sympathetic preganglionic neuron morphology	41157
SCI	41157
sympathetic preganglionic neuron morphology	41165
We	41209
T4 transection	41231
changes	41263
morphology of sympathetic preganglionic neurons	41274
morphology	41274
sympathetic preganglionic neurons	41288
both OECtreated and control groups	41325
an increase in soma size rostral to the injury after 9 weeks	41366
an increase	41366
soma size rostral to the injury after 9 weeks	41381
soma size rostral	41381
the injury after 9 weeks	41402
the injury	41402
9 weeks	41419
This	41428
the results of Krassiouov and Weaver	41446
the results	41446
Krassiouov and Weaver	41461
alterations of soma size	41490
alterations	41490
soma size	41505
7 and 30 days post-injury -LRB- Krassioukov and Weaver , 1995b , 1996 -RRB-	41542
7 and 30 days post-injury	41542
7 and 30 days	41542
Krassioukov and Weaver	41569
Krassioukov	41569
Weaver	41585
1995b , 1996	41593
1995b	41593
1996	41600
We	41607
the repeated exposure	41623
colorectal distension leading to dysreflexic hypertension	41648
colorectal distension leading	41648
dysreflexic hypertension	41681
spontaneous dysreflexic episodes	41717
Laird	41775
et al. , 2006	41781
et al.	41781
2006	41789
the soma size of these cells	41813
the soma size	41813
these cells	41830
Activity in locomotor circuits	41843
Activity	41843
locomotor circuits	41855
structural plasticity	41899
changes in electrophysiological properties	41922
changes	41922
electrophysiological properties	41933
altered function	41969
the spinal cord -LRB- Cai et al. , 2006 ; Wolpaw , 2007 -RRB-	41993
the spinal cord	41993
Cai	42010
et al. , 2006 ; Wolpaw , 2007	42014
et al.	42014
2006 ; Wolpaw	42022
2006	42022
Wolpaw	42028
2007	42036
size of the somata of rostral preganglionic neurons	42061
size	42061
the somata of rostral preganglionic neurons	42069
the somata	42069
rostral preganglionic neurons	42083
their hyperactivity secondary to dysreflexia	42138
their hyperactivity secondary	42138
dysreflexia	42171
an improved ability	42199
these cells	42222
the hypertension -LRB- Dunlop , 2008 -RRB-	42248
the hypertension	42248
Dunlop	42266
2008	42274
Caudal to the transection , Krassioukov and Weaver	42281
Caudal	42281
the transection , Krassioukov and Weaver	42291
the transection	42291
Krassioukov	42308
Weaver	42324
a temporary decrease	42340
morphometric parameters	42364
7 days	42391
30 days	42418
this	42458
the development of autonomic dysreflexia	42477
the development	42477
autonomic dysreflexia	42496
This hypothesis	42519
further	42538
findings of transient denervation	42559
findings	42559
transient denervation	42571
subsequent re-innervation	42597
postganglionic sympathetic neurons	42626
Ireland , 1999 ; Maehlen and Nja , 1984	42662
Ireland	42662
1999 ; Maehlen and Nja	42671
1999	42671
Maehlen and Nja	42677
1984	42694
This	42701
observations of Leman and Sequeira -LRB- 2002 -RRB-	42731
observations	42731
Leman and Sequeira	42747
2002	42767
an activation of adrenal preganglionic neurons	42787
an activation	42787
adrenal preganglionic neurons	42804
autonomic dysreflexia at 4 weeks	42841
autonomic dysreflexia	42841
4 weeks	42866
T4 transection	42880
our results	42905
the changes observed by Krassioukov and Weaver	42930
the changes	42930
Krassioukov and Weaver	42954
no significant differences from injury	42998
no significant differences	42998
injury	43030
9 weeks	43069
4.5	43078
OECs and sympathetic preganglionic neuron morphology	43083
OECs	43083
sympathetic preganglionic neuron morphology	43092
the effect of transection injury	43144
the effect	43144
transection injury	43158
itself	43177
we	43185
OEC treatment	43204
the morphology of the sympathetic preganglionic neurons	43227
the morphology	43227
the sympathetic preganglionic neurons	43245
rostral and caudal to the injury site	43288
rostral and caudal	43288
the injury site	43310
the OEC treatment	43338
increases	43368
dendritic length	43381
larger dendritic arbours	43399
increased synaptic inputs	43440
We	43467
this	43485
enhanced activity	43504
sympathetic tone	43540
the vascular beds above the injury	43560
the vascular beds	43560
the injury	43584
Such increased tone	43596
the upper-body vessels	43636
catecholamines	43688
the injury during autonomic dysreflexia	43723
the injury	43723
autonomic dysreflexia	43741
their ability to counterregulate against dysreflexic hypertension	43782
dysreflexic hypertension	43823
A recent study in our laboratory -LRB- Laird et al. , 2008 -RRB-	43849
A recent study	43849
our laboratory -LRB- Laird et al. , 2008 -RRB-	43867
our laboratory	43867
Laird	43883
et al. , 2008	43889
et al.	43889
2008	43897
blood vessels above as well as below the injury	43918
blood vessels	43918
the injury	43955
noradrenaline following SCI	43990
noradrenaline	43990
SCI	44014
a partial mediation against such an increase	44029
a partial mediation	44029
such an increase	44057
a potential mechanism of the OEC effect	44083
a potential mechanism	44083
the OEC effect	44108
sympathetic preganglionic neurons of the OEC-treated animals	44134
sympathetic preganglionic neurons	44134
the OEC-treated animals	44171
smaller somata	44202
those of the control animals	44229
those	44229
the control animals	44238
fact	44266
those of the intact animals	44283
those	44283
the intact animals	44292
This	44312
size	44327
a less evolved dysreflexic effect on the vascular beds below the SCI	44344
a less	44344
dysreflexic effect	44359
the vascular beds	44381
the SCI	44405
the OEC treatment	44419
recovery from autonomic dysreflexia	44458
recovery	44458
autonomic dysreflexia	44472
differential changes	44513
sympathetic neurons	44537
rostral and caudal vascular beds	44568
rostral	44568
caudal vascular beds	44580
addition	44617
other mechanisms	44627
e.g. peptidergic primary	44645
e.g.	44645
the dorsal horn , plasticity of lumbosacral propriospinal neurons	44692
the dorsal horn	44692
plasticity of lumbosacral propriospinal neurons	44709
plasticity	44709
lumbosacral propriospinal neurons	44723
Afferent	44811
a morphometric analysis of preganglionic neurons in the presence of living OECs	44845
a morphometric analysis	44845
preganglionic neurons in the presence of living OECs	44872
preganglionic neurons	44872
the presence of living OECs	44897
the presence	44897
living OECs	44913
interesting avenues	44943
further research	44967
4.6	44985
Mechanisms of OEC effect Previous studies	44990
Mechanisms	44990
OEC effect Previous studies	45004
regeneration	45046
spinal projections	45073
rats	45095
transplants of OECs	45115
transplants	45115
OECs	45130
complete cord transections	45141
Lu et al. , 2001 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000	45182
Lu	45182
et al. , 2001 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000	45185
et al. , 2001	45185
et al.	45185
2001	45193
Ramon-Cueto et al. , 1998	45199
Ramon-Cueto	45199
et al. , 1998	45211
et al.	45211
1998	45219
Ramon-Cueto et al. , 2000	45225
Ramon-Cueto	45225
et al. , 2000	45237
et al.	45237
2000	45245
contrast	45255
we	45270
any signs of regeneration	45291
any signs	45291
regeneration	45304
This	45318
several factors	45339
It	45356
the properties	45373
olfactory mucosa-derived OECs	45391
Lu	45439
et al.	45442
olfactory bulb-derived OECs -LRB- used by Ramon-Cueto et al. -RRB-	45457
olfactory bulb-derived OECs	45457
Ramon-Cueto	45494
et al.	45506
the outcomes	45543
their transplantation	45559
Au and Roskams , 2003 ; Jani and Raisman , 2004 ; Richter et al. , 2005	45582
Au and Roskams	45582
2003 ; Jani and Raisman , 2004 ; Richter et al.	45598
2003	45598
Jani and Raisman , 2004 ; Richter et al.	45604
Jani and Raisman , 2004	45604
Jani and Raisman	45604
2004	45622
Richter et al.	45628
Richter	45628
et al.	45636
2005	45644
the purity of the cell cultures	45661
the purity	45661
the cell cultures	45675
a role	45702
the overall regenerative potential of the OEC transplants.While	45712
the overall regenerative potential	45712
the OEC transplants.While	45750
the highly purified transplants	45776
95	45819
100 % of OECs -LRB- used here -RRB-	45822
100 %	45822
OECs -LRB- used here -RRB-	45830
OECs	45830
examination of the regenerative properties of OECs	45857
examination	45857
the regenerative properties of OECs	45872
the regenerative properties	45872
OECs	45903
contamination of the OEC cultures with olfactory fibroblasts	45916
contamination	45916
the OEC cultures with olfactory fibroblasts	45933
the OEC cultures	45933
olfactory fibroblasts	45955
an important role	45986
expression	46007
their regenerative properties -LRB- Li et al. , 1997 ; Li et al. , 1998 -RRB-	46021
their regenerative properties	46021
Li	46052
et al. , 1997 ; Li et al. , 1998	46055
et al.	46055
1997 ; Li et al.	46063
1997	46063
Li et al.	46069
Li	46069
et al.	46072
1998	46080
the lack of regeneration in the descending spinal tracts	46094
the lack	46094
regeneration in the descending spinal tracts	46106
regeneration	46106
the descending spinal tracts	46122
other mechanisms	46152
changes in the adjacent neuronal networks	46178
changes	46178
the adjacent neuronal networks	46189
alterations in the secondary injury spread and inflammatory response	46223
alterations	46223
the secondary injury spread and inflammatory response	46238
the secondary injury spread	46238
inflammatory response	46270
the observed functional effects	46323
we	46361
significant changes in the sympathetic preganglionic neurons	46378
significant changes	46378
the sympathetic preganglionic neurons	46401
the injury site , which were triggered by the OEC transplants	46451
the injury site	46451
the OEC transplants	46492
It	46513
OECs	46550
axonal and dendritic regrowth	46569
injured neurons	46602
direct contact and secretion	46626
soluble factors -LRB- Chung et al. , 2004 ; Kafitz and Greer , 1998 -RRB-	46658
soluble factors	46658
Chung	46675
et al. , 2004 ; Kafitz and Greer , 1998	46681
et al.	46681
2004 ; Kafitz and Greer	46689
2004	46689
Kafitz and Greer	46695
1998	46713
We	46720
the ability	46738
OECs transplanted within a Gelfoam block to infiltrate the host spinal cord	46753
OECs	46753
a Gelfoam block	46778
the host spinal cord	46808
The OECs	46847
the vicinity of ingrowing processes of the host neurons	46888
the vicinity	46888
ingrowing processes of the host neurons	46904
ingrowing processes	46904
the host neurons	46927
we	46955
any effect	46977
the OEC transplants on the morphology of the host	46991
the OEC transplants	46991
the morphology of the host	47014
the morphology	47014
the host	47032
sympathetic preganglionic neurons	47041
the overall sympathetic output to the peripheral effectors	47096
the overall sympathetic output	47096
the peripheral effectors	47130
soluble factors rather than direct contact	47190
soluble factors	47190
direct contact	47218
OECs	47234
messenger RNA and protein	47260
neurotrophic factors	47290
sympathetic preganglionic neurons	47325
NGF , BDNF and GDNF	47368
Boruch et al. , 2001 ; Vincent et al. , 2005 ; Woodhall et al. , 2001	47388
Boruch	47388
et al. , 2001 ; Vincent et al. , 2005 ; Woodhall et al. , 2001	47395
et al. , 2001	47395
et al.	47395
2001	47403
Vincent et al. , 2005	47409
Vincent	47409
et al. , 2005	47417
et al.	47417
2005	47425
Woodhall et al. , 2001	47431
Woodhall	47431
et al. , 2001	47440
et al.	47440
2001	47448
These factors	47455
an increase	47479
the size of sympathetic preganglionic somata and axons	47494
the size	47494
sympathetic preganglionic somata and axons	47506
sympathetic preganglionic somata	47506
axons	47543
synaptic input to postganglionic neurons	47558
synaptic input	47558
postganglionic neurons	47576
preganglionic neurons	47611
target-deprived cell death	47638
Nja and Purves	47666
Nja	47666
Purves	47674
1978 ; Schober et al. , 1999	47682
1978	47682
Schober et al. , 1999	47688
Schober	47688
et al. , 1999	47696
et al.	47696
1999	47704
Release of BDNF , GDNF or NGF by transplanted OECs	47711
Release of BDNF , GDNF	47711
Release	47711
BDNF , GDNF	47722
NGF by transplanted OECs	47736
NGF	47736
transplanted OECs	47743
a potential mechanismfor	47775
the effects on preganglionic neurons described here	47800
the effects	47800
preganglionic neurons described here	47815
preganglionic neurons	47815
the present study	47871
the OEC treatment	47889
differential changes	47918
sympathetic preganglionic neurons rostral and caudal	47942
the SCI	47998
It	48007
demand for trophic factors	48027
demand	48027
trophic factors	48038
preganglionic neurons	48090
intact descending innervation	48117
those deprived of descending inputs	48192
those	48192
descending inputs	48210
development	48236
neurotrophins	48249
modulators	48270
activity-dependent plasticity	48284
Bibel and Barde	48327
2000	48344
instance	48356
the effect	48365
BDNF on dendritic length and branching in retinal ganglion cells	48379
BDNF on dendritic length	48379
BDNF	48379
dendritic length	48387
retinal ganglion cells	48421
their activity -LRB- Cohen-Cory , 1999 -RRB-	48460
their activity	48460
Cohen-Cory	48476
1999	48488
the effects	48506
trophic factors	48521
the sympathetic preganglionic neuronal populations rostral and caudal to the SCI	48540
the sympathetic preganglionic neuronal populations rostral and caudal	48540
the SCI	48613
their activity	48647
other function-related variables	48676
the intensity	48718
their inputs or properties of the neuronal circuits in which they participate	48735
their inputs or properties	48735
the neuronal circuits in which they participate	48765
the neuronal circuits	48765
they	48796
Such interactions	48814
identification	48868
the effects	48886
trophic factors	48901
different subpopulations	48920
sympathetic preganglionic neurons in the injured spinal cord	48948
sympathetic preganglionic neurons	48948
the injured spinal cord	48985
interesting questions for future research	49019
interesting questions	49019
future research	49045
